The present application relates generally to treatment devices, systems, and methods for removing heat from subcutaneous lipid-rich cells; more particularly, but not exclusively, several embodiments are directed toward a treatment device including an actuator such as a vibration device, a pneumatic device and/or a massage device and at least one treatment unit to affect subcutaneous lipid-rich cells.
Excess body fat, or adipose tissue, can detract from personal appearance and athletic performance. Excess adipose tissue may be present in various locations of the body, including, for example, the thigh, buttocks, abdomen, knees, back, face, arms, and other areas. Moreover, excess adipose tissue is thought to magnify the unattractive appearance of cellulite, which forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of adipose tissue are often considered to be unappealing. Moreover, significant health risks may be associated with higher amounts of excess body fat. An effective way of controlling or removing excess body fat therefore is needed.
Liposuction is a method for selectively removing adipose tissue to “sculpt” a person's body. Liposuction typically is performed by plastic surgeons or dermatologists using specialized surgical equipment that invasively removes subcutaneous adipose tissue via suction. One drawback of liposuction is that it is a surgical procedure, and the recovery may be painful and lengthy. Moreover, the procedure typically requires the injection of tumescent anesthetics, which is often associated with temporary bruising. Liposuction can also have serious and occasionally even fatal complications. In addition, the cost for liposuction is usually substantial. Other emerging techniques for removal of subcutaneous adipose tissue include mesotherapy, laser-assisted liposuction, and high intensity focused ultrasound.
Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting, or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or negative reaction. Furthermore, fat loss in selective areas of a person's body cannot be achieved using general or systemic weight-loss methods.
Other non-invasive treatment methods include applying heat to a zone of subcutaneous lipid-rich cells. U.S. Pat. No. 5,948,011 discloses altering subcutaneous body fat and/or collagen by heating the subcutaneous fat layer with radiant energy while cooling the surface of the skin. The applied heat denatures fibrous septae made of collagen tissue and may destroy fat cells below the skin, and the cooling protects the epidermis from thermal damage. This method is less invasive than liposuction, but it still may cause thermal damage to adjacent tissue, and can also be painful and unpredictable.
Additional methods of reducing subcutaneous adipocytes cool or otherwise selectively remove or target them, as disclosed for example in U.S. Patent Publication Nos. 2003/0220674 and 2005/0251120, the entire disclosures of which are incorporated herein. These publications disclose, among other things, the concept of reducing the temperature of subcutaneous adipocytes to selectively affect them without damaging the cells in the epidermis and other surrounding tissue. Although the methods and devices disclosed in these publications are promising, several improvements for enhancing the implementation of these methods and devices would be desirable.
In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the drawings.
A. Overview
This document describes devices, systems, and methods for cooling subcutaneous adipose tissue. The term “subcutaneous tissue” means tissue lying beneath the dermis and includes subcutaneous fat, or adipose tissue, which primarily is composed of lipid-rich cells, or adipocytes. Several of the details set forth below are provided to describe the following embodiments and methods in a manner sufficient to enable a person skilled in the relevant art to practice, make and use them. Several of the details and advantages described below, however, may not be necessary to practice certain embodiments and methods of the invention. Additionally, the invention may include other embodiments and methods that are within the scope of the claims but are not described in detail.
Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the occurrences of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. The headings provided herein are for convenience only and do not limit or interpret the scope or meaning of the claimed invention.
The present invention is directed toward a treatment device for removing heat from subcutaneous lipid-rich cells of a subject and methods for using such a device. The treatment device includes an actuator that provides mechanical energy to the tissue. The mechanical energy provided may include a vibratory component that can range between low and ultra-high frequencies, and such energy may include various combinations of two or more frequencies tailored to produce the desired effect on the subcutaneous tissue. According to an embodiment, for example, disruption of adipose tissue cooled by an external treatment device may be enhanced by vibrating the cooled tissue. As applied to the tissue, then, such vibration may impart a vibratory effect, a massage effect, a pulsatile effect, combinations thereof, etc.
Several embodiments of treatment devices for removing heat from subcutaneous lipid-rich cells include at least one actuator and a treatment unit. The actuator may connect directly to the treatment unit, or the actuator may be affixed to a housing for the treatment unit. Alternatively, the treatment device may further include a flexible substrate containing a treatment unit and the actuator is connected to the flexible substrate. The actuator may provide mechanical energy to the tissue. This may be done in a number of different ways; for example, varying mechanical energy, such as vibratory energy, may be imparted through the applicator. Alternatively, or additionally the tissue may be directly manipulated with varying pneumatic pressure. The actuator may include a motor with an eccentric weight or other vibratory motors such as hydraulic motors, electric motors, solenoids, other mechanical motors, or piezoelectric shakers to provide the energy to the treatment site. The treatment units may use a number of cooling technologies including, for example, thermoelectric coolers, recirculating chilled fluid, vapor compression elements, or phase change cryogenic devices. One skilled in the art will recognize that there are a number of other cooling technologies and mechanical movement technologies that could be used such that the treatment units and mechanical devices need not be limited to those described herein.
Another embodiment of a treatment device may include one or more actuators coupled to at least one of a plurality of interconnected hinged or coupled segments; the hinged or coupled segments allow the treatment device to conform to a body portion. The one or more actuators may rigidly be affixed or releasably coupled to any portion of the interconnected hinged or coupled segment. Alternatively, the one or more actuators may be on or embedded in a flexible substrate which further contains the treatment units.
In yet another embodiment, a treatment device comprises one or more actuators controllable to provide varying intensity, frequency, location and/or duration of motion during treatment. The motion profile can, for example, be configured to provide motion along a selected region of the treatment device for a pre-selected or controlled time period. Alternatively, the motion profile may, for example, be configured to provide periods of increased intensity. In other embodiments, the motion profile may vary over time to provide a decreasing or an increasing intensity during treatment according to a predetermined pattern. In still other embodiments, different actuators may simultaneously provide different types of motion or motion of varying intensity, frequency, location and/or duration between or among the actuators, or some actuators may be deactivated while others are activated in varying patterns throughout the course of treatment.
Additional embodiments disclosed below are directed toward methods of affecting lipid-rich cells by applying a treatment device and imparting mechanical energy to the target cells from one or more actuators. The actuator may provide mechanical energy imparted to the tissue. Depending on the frequency and amplitude of the mechanical energy, the mechanical energy may yield an effect such as a vibratory effect, a massage effect, a pulsatile effect, or any combination thereof that sends mechanical energy to the patient via or in connection with the treatment device. One embodiment of such a method includes arranging a treatment device in a desired configuration, cooling a heat exchanging surface of a treatment unit to a desired temperature, placing the cooled heat exchanging surface proximate to the subject's skin, activating an actuator that imparts mechanical energy to the tissue, and reducing the temperature of a region such that lipid-rich cells in the region are affected while non-lipid-rich cells in the region generally are not affected. Alternatively, the actuator and the treatment units may be on and/or within a flexible substrate.
Further embodiments disclosed below are directed toward systems for efficiently removing heat from subcutaneous lipid-rich cells. An embodiment of a system includes a treatment device having one or more actuators coupled to a hinge, frame, substrate or other portion of the treatment device. The actuator is configured to impart mechanical motion relative to the skin of a patient, including positive and negative pressure; for example, the actuator may include a pneumatic feature, such as vacuum, for drawing and/or pressuring the subject's tissue away from and/or towards, respectively, the treatment device. In another embodiment, the actuator may include a vibratory device for providing mechanical vibration transferred to the subject's tissue via the treatment device. In yet another embodiment, the actuator may provide mechanical energy to produce a massage effect, thus providing mechanical massage to the treated region. When placed proximate to a subject's skin, the treatment device is capable of reducing a temperature of a region such that lipid-rich cells in the region are affected while non-lipid-rich cells in the epidermis and/or dermis are not generally affected.
B. System for More Effectively Selectively Reducing Lipid-Rich Cells
The system 100 may further include a treatment unit 106 and supply and return fluid lines 108a-b between the treatment device 104 and the fluid source 107. The fluid source 107 can remove heat from a coolant to a heat sink and provide a chilled coolant to the treatment device 104 via the fluid lines 108a-b. Examples of the circulating coolant include water, glycol, synthetic heat transfer fluid, oil, a refrigerant, and/or any other suitable heat-conducting fluid. The fluid lines 108a-b may be hoses or other conduits constructed from polyethylene, polyvinyl chloride, polyurethane, and/or other materials that can accommodate the particular circulating coolant. The treatment unit 106 may be a refrigeration unit, a cooling tower, a thermoelectric chiller, or any other device capable of removing heat from a coolant. Alternatively, a municipal water supply (i.e., tap water) may be used in place of the treatment unit.
As explained in more detail below, the treatment device 104 includes at least one actuator 105 and at least one treatment unit. The treatment unit may be a Peltier-type thermoelectric element, and the treatment device 104 may have a plurality of individually controlled treatment units to create a custom spatial cooling profile and/or a time-varying cooling profile. The system 100 may further include a power supply 110 and a processing unit 114 operatively coupled to the treatment device 104 and the actuator 105. In one embodiment, the power supply 110 provides a direct current voltage to a thermoelectric treatment device 104 and/or the actuator 105 to remove heat from the subject 101. The processing unit 114 may monitor process parameters via sensors (not shown) placed proximate to the treatment device 104 through power line 116 to, among other things, adjust the heat removal rate based on the process parameters. The processing unit 114 may further monitor process parameters to adjust actuator 105 based on the process parameters. The processing unit 114 may be in direct electrical communication with treatment device 104 through electrical line 112 as shown in
In another aspect, the processing unit 114 may be in electrical or other communication with an input device 118, an output device 120, and/or a control panel 122. The input device 118 may be a keyboard, a mouse, a touch screen, a push button, a switch, a potentiometer, any combination thereof, and any other device or devices suitable for accepting user input. The output device 120 may be include a display screen, a printer, a medium reader, an audio device, any combination thereof, and any other device or devices suitable for providing user feedback. The control panel 122 may include visual indicator devices or controls (lights, numerical displays, etc.) and/or audio indicator devices or controls. In alternative embodiments, the control panel 122 may be contained in, attached to, or integrated with the treatment device 104. In the embodiment shown in
C. Actuator for Use with a Treatment Device
D. Treatment Device Having an Actuator Such as a Vibratory Device
According to one embodiment, an actuator 105 is affixed by screws 154 or other mechanical fixation devices to a housing 156 of the treatment device 104 to transmit mechanical energy through the treatment device 104 to the tissue of a patient. Alternatively, the actuator 105 may be strapped in place proximate to the treatment device 104 to transmit mechanical energy through the treatment device 104 of the tissue of the patient. According to still further embodiments, the actuator 105 may be incorporated into the treatment device 104 to provide an integrated treatment device with an activator for providing mechanical energy.
According to alternative embodiments, the treatment device 104 includes a plurality of links that are mechanically coupled with a plurality of hinges and a single actuator to transfer mechanical vibratory energy through adjacent links to the skin. Alternately, the actuator can be incorporated into more than one link, or a plurality of actuators may be used with a single treatment device.
In specific embodiments of the motor 150, the eccentric weight may be a weight machined out of brass; alternatively, the mass may be fabricated from steel, aluminum, alloys thereof, high density polymeric materials, or any other relatively dense material. According to further embodiments, the motor used is a brushed DC motor; alternatively, any electric motor could be used, or any other means of rotating the mass as is known in the art.
The actuator 105 need not have a rotating eccentric weight; rather, other embodiments may have an electrical coil or the like to create a varying or pulsing energy. The electrical coil, for example, may include a solenoid, a vibrating armature or a voice coil. According to an embodiment using a solenoid, a coil is energized to create a magnetic field that moves a steel or iron armature. The armature may be attached to a mass and can be driven into a hard stop to produce a pulse. If the hard stop is mechanically coupled to the device applied to the skin, this energy will be transferred into the tissue. This method of imparting mechanical energy to lipid-rich cells so to create a massage or massage-like effect is suited, but not necessarily limited, to lower frequencies and higher impulse energies.
A specific embodiment of a vibrating armature or voice coil has a coil driven by an alternating current to move or oscillate the armature back and forth. The inertia of this motion may be transferred through the link into the tissue to provide an actuator for enhancing the vibratory effect on the lipid-rich cells.
According to still further embodiments, the mechanical force may create a massage massage-like effect using a water hammer. Water, or any of a number of other heat transfer fluids suitable for cooling the thermoelectric coolers, can have significant mass, and when flowing through tubing, these fluids can commensurately have significant momentum. By quickly halting the flow of such a fluid, such as, e.g., by placing a solenoid valve in the fluid line and closing the flow path, a properly designed system transfers the momentum of the fluid to the treatment device 104 and into the tissue. According to aspects of this embodiment, such a water hammer or similar momentum-transferring arrangement is suited to low frequencies. Further, such an arrangement may reduce the heat transfer rate, which may be desirable for certain applications.
In operation, the motor 150 shown in
The illustrated embodiment of the actuator as shown in
In addition, the illustrated embodiment may provide acceleration and enhancement of the ischemic reperfusion damage to adipose tissue through mechanical massage or vibration. Further, the illustrated embodiment of the actuator and the treatment device combine to provide an enhanced ability to disrupt crystallized adipose cells and further affect lipid-rich cells.
E. Treatment Device Having an Actuator Such as a Vacuum Device
As described herein, techniques for incorporating massage into a treatment device 105 may include using a pressure differential to draw the skin against a thermally controlled plate or plates. In an actuator such as the vacuum device 160 shown in
The vacuum device 160 defines the reservoir 430 for receiving tissue of a subject during treatment. The vacuum device 160 may further include treatment units 408a, 408b positioned at opposite sides of the vacuum device 160. Alternatively, the treatment units 408a, 408b may be adjacent one another. Further, vacuum device 160 may comprise a vacuum cup and a single treatment unit or more than two treatment units. As shown in the example of
The heat exchanging interface 420 may also include at least one sensing element (not shown) proximate to the heat exchanging interface 420. The sensing element, for example, may be generally flush with the heat exchanging interface 420. Alternatively, it may be recessed or protrude from the surface. The sensing element may include a temperature sensor, a pressure sensor, a transmissivity sensor, a bio-resistance sensor, an ultrasound sensor, an optical sensor, an infrared sensor, a sensor for measuring blood flow, or any other desired sensor. In one embodiment, the sensing element may be a temperature sensor configured to measure the temperature of the heat exchanging interface 420 and/or the temperature of the skin of the subject. For example, the temperature sensor may be configured as a probe or as a needle that penetrates the skin during measurement. Examples of suitable temperature sensors include thermocouples, resistance temperature devices, thermistors (e.g., neutron-transmutation-doped germanium thermistors), and infrared radiation temperature sensors. In another embodiment, the sensing element may be an ultrasound sensor configured to measure the thickness of a fat layer in the subject or crystallization of subcutaneous fat in the treatment region of a subject. In yet another embodiment, the sensing element may be an optical or infrared sensor configured to monitor an image of the treatment region to detect, for example, epidermal physiological reactions to the treatment. In yet another embodiment, the sensing element may be a device to measure blood flow. The sensing element may be in electrical communication with the processing unit 114 via, for example, a direct wired connection, a networked connection, and/or a wireless connection.
The vacuum device 160 may further include a mounting element 406 that couples the treatment units 408a, 408b to the vacuum device 160. The mounting element 406, for example, may be a bracket, frame or other suitable fixture. The treatment units 408a, 408b may include a heat sink 402 with a cover 401, and a thermoelectric cooler 404 disposed between the heat sink 402 and the heat exchanging interface 420. The thermoelectric cooler 404 may be a single Peltier-type element or a plurality of Peltier-type elements. One suitable thermoelectric cooler is a Peltier-type heat exchanging element (model #CP-2895) produced by TE Technology, Inc. in Traverse City, Mich.
In the illustrated embodiment, the heat sink 402 includes a serpentine shaped fluid conduit at least partially embedded in the heat sink 402. In the illustrated embodiment, the heat sink includes fluid ports 410a, 410b that may be coupled to a circulating fluid source (not shown) via the fluid lines 108a-b. In other embodiments, the heat sink 402 may include a plate-type heat exchange, a tube and a shell heat exchanger, and/or other types of heat exchanging devices.
Vacuum pressure may be supplied by any pump (e.g., pump 407 shown in
By alternating between two different vacuum levels inside the vacuum device 160, the force applied to the tissue will concomitantly increase and decrease, having the effect of a massaging action on the tissue. This may be accomplished, for instance, by ensuring the minimum vacuum level is high enough to keep the tissue drawn into the vacuum device 160, and have the tissue drawn further inside vacuum device 160 when the higher vacuum level is applied. If the tissue is drawn inside the applicator to the largest extent possible, friction between the walls of the applicator and the tissue may cause the tissue to maintain its overall position or assist the tissue in maintaining such a position. The change in vacuum pressure level at a desired frequency pulses the tissue, moving the area of tissue exposed to the vacuum to alternating positions within vacuum device 160. This is possible in part because initially, a higher pressure differential is required to draw the tissue past the sealing surface of the reservoir 430 and up inside the reservoir 430; however, once the tissue has been drawn into place, the force (and therefore the vacuum level) required to hold the tissue in place is lower. In this embodiment, the lower vacuum level (nearer to ambient pressure) may be very low, potentially as low as 1 inch of Hg or lower. The higher pulsing pressure can be 2 inches of mercury vacuum or higher. In operations, increasing the difference between the two vacuum levels increases the massage force. Further, increasing the cycle rate between the two pressures increases the massage frequency. Accordingly, the tissue can be pulsed in the range of approximately 0.1 Hz or lower and 10 Hz or higher. It is also possible to select the two vacuum levels (and possibly other parameters such as frequency, etc.) sufficient to draw the tissue into the vacuum device reservoir 430 and to impart a massage or pulsatile effect to the tissue while keeping the tissue position relatively constant inside reservoir 430 as alternating levels of vacuum are applied. This may be accomplished, for example, by decreasing the relative difference between vacuum levels applied to the tissue but by keeping the lower vacuum level high enough to keep the tissue drawn into the reservoir 430 of vacuum device 160 during treatment.
One method of creating this pneumatic massaging action is with a variable speed pump. Using pressure feedback to control the pump speed, the pump may electronically be controlled between two different vacuum levels. According to this embodiment, there is a mechanical lag in the time it takes the pump to change speeds, therefore, this embodiment may not be capable of pulsing at a frequency as high as some of the other embodiments described herein. According to yet another embodiment, a large piston is coupled to the treatment device 104; the piston is driven back and forth, either pneumatically or mechanically, to create a pressure wave in the system.
In an alternate embodiment shown in
Alternately, as shown in
As shown in
The illustrated embodiments of the actuator 105 combined with the treatment device 104 can enhance disruption of adipose tissue cooled by an external skin treatment device. Further, the illustrated embodiment may reduce treatment time, reduce discomfort to the patient and increase efficacy of treatment. For example, in an alternative embodiment, the vacuum device 160 may be employed without any vibratory, pulsing, or massage effect on the tissue drawn therein; rather, the vacuum may statically draw tissue into the reservoir 430 of the vacuum device 160, and hold the tissue in the reservoir 430 while cooling through a portion of or up to the entire duration of the treatment time, and releasing it only when the cooling treatment protocol is completed. Without being bound by theory, it is believed that while drawn into the vacuum device reservoir 430, the relative physical isolation of the target subcutaneous adipose tissue beneath the epidermis from the thermal mass of tissue normally below such tissue that is not drawn into reservoir 430 (e.g., underlying vasculature, muscles, etc.) and the reduction in blood circulation through the tissue drawn into reservoir 430 allow for a more efficient temperature reduction of lipid-rich cells such that the lipid-rich cells are substantially affected while non-lipid-rich cells in the epidermis are not substantially affected. This may have the advantage of increasing the efficacy of treatment and/or reducing treatment times.
F. Treatment Device Having a Plurality of Treatment Units
The treatment unit housings 204a-g are connected to the heat exchanging elements (not shown) by attachment device 206. The attachment device may be any mechanical attachment device such as a screw or pin as is known in the art. The plurality of treatment unit housings 204a-g may have many similar features. As such, the features of the first treatment unit housing 204a are described below with reference symbols followed by an “a,” corresponding features of the second treatment unit housing 204b are shown and noted by the same reference symbol followed by a “b,” and so forth. The treatment unit housing 204a may be constructed from polymeric materials, metals, ceramics, woods, and/or other suitable materials. The example of the treatment unit housing 204a shown in
The control system housing 202 may house that actuator 105 and/or a processing unit for controlling the treatment device 800 and/or fluid lines 108a-b and/or electrical power and communication lines. The control system housing 202 includes a harness port 210 for electrical and supply fluid lines (not shown for purposes of clarity). The control system housing 202 may further be configured to serve as a handle for a user of the treatment device 800. Alternatively, a plurality of actuators (not shown) may be contained on any one of the treatment unit housing segments 204a-g.
As shown in
The treatment device 104 includes a frame 304 having a plurality of rotatably connected segments 305a-g. The rotatably connected segments 305a-g are connected by hinges 306a-f, and, according to one embodiment, the actuator 105 is attached to at least one of the hinges 306a-f. Alternatively, the rotatably connected segments 305a-g of the frame 304 could be connected by a connection that allows rotation, such as a pin, a living hinge or a flexible substrate such as webbing or fabric or the like. According to one aspect of the invention, the links or hinges are made of plastic to insulate the treatment units from each other.
G. Operation of the Treatment Device
Without being bound by theory, it is believed that in operation effective cooling from the treatment device, which cools through conduction, depends on a number of factors. Exemplary factors that impact heat removal from the skin area and related tissue are the surface area of the treatment unit, the temperature of the interface member and the mechanical energy delivered to the tissue.
According to illustrated embodiments, the actuator 105 and the treatment device 104 combine to enhance disruption of cooled adipose tissue. Further, the illustrated embodiments may provide reduced treatment time, reduced discomfort to the patient and increased efficacy of treatment.
The illustrated embodiments can provide the treatment device 104 and the actuator 105 which reduce subcutaneous lipid-rich cells generally without collateral damage to non-lipid-rich cells in the treatment region. In general, lipid-rich cells can be affected at low temperatures that do not affect non-lipid-rich cells. As a result, lipid-rich cells, such as subcutaneous adipose tissue, can be affected while other cells in the same region are generally not damaged even though the non-lipid-rich cells at the surface are subject to even lower temperatures. The mechanical energy provided by the actuator further enhances the affect on lipid-rich cells by disrupting the affected lipid-rich cells.
In alternative embodiments, a cryoprotectant is used with the treatment device to, among other advantages, prevent freezing of the tissue during treatment as is described in U.S. patent application Ser. No. 11/741,271, filed Apr. 27, 2007, and entitled “Cryoprotectant for use with a Treatment Device for Improved Cooling of Subcutaneous Lipid-Rich Cells,” herein incorporated in its entirety by reference.
H. Spatially Controlled Treatment Unit Profile
According to aspects of the invention, a spatially controlled profile can provide more efficient cooling to the treatment region. The plurality of actuators and/or thermoelectric coolers allows the treatment device to accommodate spatial cooling. For example, actuators may be contained at the perimeter of the treatment device to provide additional mechanical energy (via increased amplitude, or intensity, or via a longer duration, or any combination thereof) than mechanical energy provided by actuators contained at the interior of the treatment device because of different boundary conditions in the different areas of the treatment zone. Alternatively, individual actuators, or groups of individual actuators, may be actuated at varying times or with varying frequency in any combination to provide a varying spatial profile of imparted mechanical energy over the treatment region.
According to aspects of the invention, the device can accommodate spatially controlled treatment profiles which may provide at least the following advantages: (1) increased efficiency; (2) decreased power consumption with comparable efficacy; (3) increased patient comfort; or (4) decreased treatment time. For example, according to aspects of the invention, the plurality of actuators will allow adjustment for anatomical differences between patients by selectively enabling or disabling portions of the apparatus based on anatomical differences of the patient. This selective enablement may be accomplished by varying both the mechanical actuation mechanism and/or the cooling profile in any number of ways.
For instance, another alternative involves the implementation of a particular pattern of controlled cooling which may be customized to match an individual patient's pattern of cellulite, or subcutaneous fat, thus increasing the efficacy of the treatment and allowing the “sculpting” or contouring of the patient's tissue to achieve a desired aesthetic or other effect. Similarly, treatment regions requiring a higher intensity of treatment may be pre-identified by ultrasound or other devices. The device can then be spatially controlled to provide higher intensity treatment to those pre-identified areas. Further advantages include increased patient comfort and safety by allowing spatial control of cooling to accommodate special features of a particular patient's anatomy (e.g., lumps such as lipomas, blemishes or scars, areas having excess hair, areas containing implants or jewelry, or areas of heightened sensitivity such as nipples or wounds).
A further advantage of spatial control of the device includes utilizing only a subset of the actuators in order to treat only the region requiring treatment. It is advantageous to use one device that can accommodate small and large treatment regions without over treating (e.g. a large device that cannot be spatially controlled) or having to move the device multiple times thus extending the treatment time (e.g. a treatment device smaller than the treatment region). Thus, according to aspects of the invention, a selected region of actuators can be controlled to provide mechanical energy to select regions. Alternatively, a first actuator of the treatment device can be turned off while a second actuator of the treatment device is activated, such that only a selected region of the subject is treated with mechanical energy, thus limiting the treatment region. Other advantageous spatially controlled patterns include treating areas within the treatment region more intensely, conserving power by alternating actuators, increasing mechanical energy at a perimeter in order to provide a uniform energy distribution across the treatment area, and a combination of these spatially controlled patterns in order to increase treatment efficacy, reduce treatment time, decrease power consumption and provide for patient comfort and safety.
It is expressly understood that embodiments of the invention specifically contemplate utilizing, via spatial control or even a randomly selected profile, varying combinations of actuation to impart mechanical energy as described herein with applying treatment devices to affect the lipid-rich cells in any number of ways (e.g., varying frequency, intensity (amplitude), duration, start and stop times, temperature, etc.), applying mechanical energy alone without cooling, applying cooling alone without mechanical energy, utilizing reheating to accelerate damage to lipid-rich cells, to achieve the desired effect.
I. Method of Applying Treatment devices
In one mode of operation, the actuator is coupled to a treatment device. The treatment device may be configured to be a handheld device such as the device disclosed in U.S. patent application Ser. No. 11/359,092, entitled “Treatment device For Removing Heat From Subcutaneous Lipid-Rich Cells”, filed on Feb. 22, 2006, herein incorporated in its entirety by reference. The treatment device may be configured to be a plurality of treatment devices contained in a flexible substrate or in a rotatable housing such as the device disclosed in U.S. patent application Ser. No. 11/528,225, entitled “Cooling Devices Having a Plurality of Controllable Treatment units to Provide a Predetermined Cooling Profile”, filed on Sep. 26, 2006, herein incorporated in its entirety by reference.
Applying the treatment device with pressure to the subject's skin or pressing against the skin can be advantageous to achieve efficient cooling. In general, the subject 101 has a body temperature of about 37° C., and the blood circulation is one mechanism for maintaining a constant body temperature. As a result, blood flow through the dermis and subcutaneous layer of the region to be treated may be viewed as a heat source that counteracts the cooling of the subdermal fat. As such, cooling the tissue of interest requires not only removing the heat from such tissue but also that of the blood circulating through this tissue. Thus, temporarily reducing or eliminating blood flow through the treatment region, by means such as, e.g., applying the treatment device with pressure, can improve the efficiency of tissue cooling and avoid excessive heat loss through the dermis and epidermis.
By cooling the subcutaneous tissue to a temperature lower than 37° C., subcutaneous lipid-rich cells can be selectively affected. In general, the epidermis and dermis of the subject 101 have lower amounts of unsaturated fatty acids compared to the underlying lipid-rich cells forming the subcutaneous tissues. Because non-lipid-rich cells usually can withstand colder temperatures better than lipid-rich cells, the subcutaneous lipid-rich cells can be selectively affected while maintaining the non-lipid-rich cells in the dermis and epidermis. An exemplary range for the treatment unit 302a-g can be from about −20° C. to about 20° C., preferably from about −20° C. to about 10° C., more preferably from about −15° C. to about 5° C., more preferably from about −10° C. to about 0° C.
The lipid-rich cells can be affected by disrupting, shrinking, disabling, destroying, removing, killing, or otherwise being altered. Without being bound by theory, selectively affecting lipid-rich cells is believed to result from localized crystallization of highly saturated fatty acids at temperatures that do not induce crystallization in non-lipid-rich cells. The crystals can rupture the bi-layer membrane of lipid-rich cells to selectively necrose these cells. Thus, damage of non-lipid-rich cells, such as dermal cells, can be avoided at temperatures that induce crystal formation in lipid-rich cells. Cooling is also believed to induce lipolysis (e.g., fat metabolism) of lipid-rich cells to further enhance the reduction in subcutaneous lipid-rich cells. Lipolysis may be enhanced by local cold exposure, inducing stimulation of the sympathetic nervous system.
The cooling assembly 308 may include a heat sink 312, a thermally conductive interface member 309, and a thermoelectric cooler 314 disposed between the heat sink 312 and the interface member 309. The thermoelectric cooler 314 may be connected to an external power supply (not shown) via connection terminals 316. In the illustrated embodiment, the heat sink 312 includes a U-shaped fluid conduit 310 at least partially embedded in a thermally conductive portion 313 of the heat sink 312. The fluid conduit 310 includes fluid ports 138a-b that may be coupled to a circulating fluid source (not shown) via the fluid lines 108a-b. In other embodiments, the heat sink 312 may include a plate-type heat exchanger, a tube and shell heat exchanger, and/or other types of heat exchanging device. The interface member 309 may include a plate constructed from a metal, a metal alloy, and/or other types of thermally conductive material. The thermoelectric cooler 314 may be a single Peltier-type element or an array of Peltier-type elements. One suitable thermoelectric cooler is a Peltier-type heat exchanging element (model #CP-2895) produced by TE Technology, Inc. in Traverse City, Mich.
Individual retention devices 318 may include a plate 330 and a plurality of fasteners 306 extending through a plurality of apertures 332 (two are shown for illustrative purposes) of the plate 330. In the illustrated embodiment, the fasteners 306 are screws that may be received by the housing 300. In other embodiments, the fasteners 306 may include bolts, clamps, clips, nails, pins, rings, rivets, straps, and/or other suitable fasteners. During assembly, the cooling assembly 308 is first at least partially disposed in the internal space 303 of the housing 300. Then, the retention devices 318 are positioned proximate to the cooling assembly 308, and the fasteners 306 are extended through the apertures 332 of the plate 330 to engage the housing 300. The fasteners 306, the plates 330, and the housing 300 cooperate to hold the cooling assembly 308 together.
By applying power to the thermoelectric cooler 314, heat may be effectively removed from the skin of the subject to a circulating fluid in the fluid conduit 310. For example, applying a current to the thermoelectric cooler 314 may achieve a temperature generally below 37° C. on the first side 315a of the thermoelectric cooler 314 to remove heat from the subject via the interface member 309. The thermoelectric cooler 314 transfers the heat from the first side 315a to the second side 315b. The heat is then transferred to the circulating fluid in the fluid conduit 310.
In operation, applying electricity to the motor 325 may cause the rotating member 328 to rotate around the body axis 327 of the motor 325. The off-centered rotating member 328 causes the vibrator 322 to be off-balanced about the body axis 327, and vibration in the frame 324 and the housing 300 may result.
J. Computing System Software Modules
In operation, the input module 944 accepts an operator input, such as process setpoint and control selections, and communicates the accepted information or selections to other components for further processing. The database module 946 organizes records, including operating parameters 954, operator activities 956, and alarms 958, and facilitates storing and retrieving of these records to and from a database 952. Any type of database organization can be utilized, including a flat file system, hierarchical database, relational database, or distributed database, such as provided by a database vendor such as Oracle Corporation, Redwood Shores, Calif.
The process module 948 generates control variables based on sensor readings 960 (e.g., sensor readings from a sensor), and the output module 950 generates output signals 962 based on the control variables. For example, the output module 950 can convert the generated control variables from the process module 948 into 4-20 mA output signals 962 suitable for a direct current voltage modulator. The processor 942 optionally can include the display module 951 for displaying, printing, or downloading the sensor readings 960 and output signals 962 via devices such as the output device 120. A suitable display module 951 can be a video driver that enables the processor 942 to display the sensor readings 960 on the output device 120.
Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise,” “comprising,” and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in a sense of “including, but not limited to.” Words using the singular or plural number also include the plural or singular number, respectively. When the claims use the word “or” in reference to a list of two or more items, that word covers all of the following interpretations of the word: any of the items in the list, all of the items in the list, and any combination of the items in the list.
U.S. patent application Ser. No. 11/750,953 and U.S. patent application Ser. No. 13/616,633 are incorporated by reference in their entireties. The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the invention can be modified, if necessary, to employ treatment devices and actuators with a plurality of treatment units, thermally conductive devices with various configurations, and concepts of the various patents, applications, and publications to provide yet further embodiments of the invention.
These and other changes can be made to the invention in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims, but should be construed to include all cooling that operates in accordance with the claims. Accordingly, the invention is not limited by the disclosure, but instead its scope is to be determined entirely by the following claims.
The present application is a continuation of U.S. patent application Ser. No. 15/815,454, filed Nov. 16, 2017, now pending, which is a continuation of U.S. patent application Ser. No. 13/616,633, filed Sep. 14, 2012, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/750,953, filed on May 18, 2007, now abandoned. These applications are incorporated by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
681806 | Mignault | Sep 1901 | A |
889810 | Robinson | Jun 1908 | A |
1093868 | Leighty | Apr 1914 | A |
2052098 | Lockett | Aug 1936 | A |
2516491 | Swastek | Jul 1950 | A |
2521780 | Dodd et al. | Sep 1950 | A |
2726658 | Chessey | Dec 1955 | A |
2766619 | Tribus et al. | Oct 1956 | A |
2851602 | Cramwinckel | Sep 1958 | A |
3093135 | Hirschhorn | Jun 1963 | A |
3132688 | Nowak | May 1964 | A |
3133539 | Eidus et al. | May 1964 | A |
3282267 | William | Nov 1966 | A |
3502080 | Hirschhorn | Mar 1970 | A |
3516411 | Adler | Jun 1970 | A |
3587577 | Smirnov et al. | Jun 1971 | A |
3591645 | Selwitz | Jul 1971 | A |
3692338 | Nick | Sep 1972 | A |
3703897 | Mack | Nov 1972 | A |
3710784 | Taylor | Jan 1973 | A |
3786814 | Armao | Jan 1974 | A |
3827436 | Stumpf et al. | Aug 1974 | A |
3841323 | Stoughton | Oct 1974 | A |
3942519 | Shock | Mar 1976 | A |
3948269 | Zimmer | Apr 1976 | A |
3986385 | Johnston et al. | Oct 1976 | A |
3993053 | Grossan | Nov 1976 | A |
4002221 | Buchalter | Jan 1977 | A |
4026299 | Sauder | May 1977 | A |
4140130 | Storm, III | Feb 1979 | A |
4149529 | Copeland | Apr 1979 | A |
4178429 | Scheffer | Dec 1979 | A |
4202336 | van Gerven et al. | May 1980 | A |
4266043 | Fujii | May 1981 | A |
4269068 | Molina | May 1981 | A |
4381009 | Del Bon et al. | Apr 1983 | A |
4396011 | Mack et al. | Aug 1983 | A |
4459854 | Richardson | Jul 1984 | A |
4470263 | Lehovec | Sep 1984 | A |
4483341 | Les | Nov 1984 | A |
4528979 | Marchenko | Jul 1985 | A |
4531524 | Mioduski | Jul 1985 | A |
4548212 | Leung | Oct 1985 | A |
4555313 | Duchane | Nov 1985 | A |
4585002 | Kissin | Apr 1986 | A |
4603076 | Bowditch | Jul 1986 | A |
4614191 | Perler | Sep 1986 | A |
4644955 | Mioduski | Feb 1987 | A |
4664110 | Schanzlin | May 1987 | A |
4700701 | Montaldi | Oct 1987 | A |
4718429 | Smidt et al. | Jan 1988 | A |
4741338 | Miyamae et al. | May 1988 | A |
4748973 | Cho | Jun 1988 | A |
4758217 | Gueret | Jul 1988 | A |
4764463 | Mason et al. | Aug 1988 | A |
4802475 | Weshahy et al. | Feb 1989 | A |
4832022 | Tjulkov et al. | May 1989 | A |
4846176 | Golden | Jul 1989 | A |
4850340 | Onishi | Jul 1989 | A |
4869250 | Bitterly | Sep 1989 | A |
4880564 | Abel et al. | Nov 1989 | A |
4905697 | Heggs | Mar 1990 | A |
4906463 | Cleary | Mar 1990 | A |
4930317 | Klein | Jun 1990 | A |
4935345 | Guilbeau et al. | Jun 1990 | A |
4961422 | Marchosky et al. | Oct 1990 | A |
4962761 | Golden | Oct 1990 | A |
4990144 | Blott | Feb 1991 | A |
5007433 | Hermsdorffer et al. | Apr 1991 | A |
5018521 | Campbell | May 1991 | A |
5024650 | Hagiwara | Jun 1991 | A |
5065752 | Sessions | Nov 1991 | A |
5069208 | Noppel et al. | Dec 1991 | A |
5084671 | Miyata et al. | Jan 1992 | A |
5108390 | Potocky et al. | Apr 1992 | A |
5119674 | Nielsen et al. | Jun 1992 | A |
5139496 | Hed et al. | Aug 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5148804 | Hill et al. | Sep 1992 | A |
5158070 | Dory | Oct 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5197466 | Marchosky et al. | Mar 1993 | A |
5207674 | Hamilton | May 1993 | A |
5221726 | Dabi | Jun 1993 | A |
5241753 | Lalevee, Sr. | Sep 1993 | A |
5264234 | Windhab et al. | Nov 1993 | A |
5277030 | Miller | Jan 1994 | A |
5314423 | Seney | May 1994 | A |
5327886 | Chiu | Jul 1994 | A |
5330745 | McDow | Jul 1994 | A |
5333460 | Lewis | Aug 1994 | A |
5334131 | Omandam et al. | Aug 1994 | A |
5336616 | Livesey et al. | Aug 1994 | A |
5339541 | Owens | Aug 1994 | A |
5342617 | Gold | Aug 1994 | A |
5351677 | Kami et al. | Oct 1994 | A |
5358467 | Milstein | Oct 1994 | A |
5362966 | Rosenthal et al. | Nov 1994 | A |
5363347 | Nguyen | Nov 1994 | A |
5372608 | Johnson, III | Dec 1994 | A |
5386837 | Sterzer | Feb 1995 | A |
5411541 | Bell | May 1995 | A |
5427772 | Hagan | Jun 1995 | A |
5433717 | Rubinsky et al. | Jul 1995 | A |
5456703 | Beeuwkes, III | Oct 1995 | A |
5472416 | Blugerman et al. | Dec 1995 | A |
5486207 | Mahawili | Jan 1996 | A |
5497596 | Zatkulak | Mar 1996 | A |
5501655 | Rolt | Mar 1996 | A |
5505726 | Meserol | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507790 | Weiss et al. | Apr 1996 | A |
5514105 | Goodman, Jr. | May 1996 | A |
5514170 | Mauch | May 1996 | A |
5516505 | McDow | May 1996 | A |
5531742 | Barken | Jul 1996 | A |
5562604 | Yablon et al. | Oct 1996 | A |
5571801 | Segall et al. | Nov 1996 | A |
5575812 | Owens | Nov 1996 | A |
5603221 | Maytal et al. | Feb 1997 | A |
5619964 | Feucht | Apr 1997 | A |
5628769 | Saringer et al. | May 1997 | A |
5634890 | Morris | Jun 1997 | A |
5634940 | Panyard | Jun 1997 | A |
5647051 | Neer | Jul 1997 | A |
5647868 | Chinn | Jul 1997 | A |
5650450 | Lovette | Jul 1997 | A |
5651773 | Perry et al. | Jul 1997 | A |
5654279 | Rubinsky et al. | Aug 1997 | A |
5654546 | Lindsay | Aug 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5665053 | Jacobs | Sep 1997 | A |
5672172 | Zupkas | Sep 1997 | A |
5700284 | Owens | Dec 1997 | A |
5725483 | Podolsky | Mar 1998 | A |
5733280 | Avitall | Mar 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5746702 | Gelfgat | May 1998 | A |
5746736 | Tankovich | May 1998 | A |
5755663 | Larsen | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5755755 | Panyard | May 1998 | A |
5759182 | Varney | Jun 1998 | A |
5759764 | Polovina | Jun 1998 | A |
5769879 | Richards | Jun 1998 | A |
5785955 | Fischer | Jul 1998 | A |
5792080 | Ookawa | Aug 1998 | A |
5800490 | Patz | Sep 1998 | A |
5814040 | Nelson | Sep 1998 | A |
5817050 | Klein | Oct 1998 | A |
5817149 | Owens | Oct 1998 | A |
5817150 | Owens | Oct 1998 | A |
5830208 | Muller | Nov 1998 | A |
5833685 | Tortal | Nov 1998 | A |
5844013 | Kenndoff | Dec 1998 | A |
5853364 | Baker et al. | Dec 1998 | A |
5865841 | Kolen | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5871526 | Gibbs | Feb 1999 | A |
5885211 | Eppstein | Mar 1999 | A |
5891617 | Watson | Apr 1999 | A |
5895418 | Saringer et al. | Apr 1999 | A |
5901707 | Gonçalves et al. | May 1999 | A |
5902256 | Benaron | May 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5944748 | Mager et al. | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5954680 | Augustine | Sep 1999 | A |
5964092 | Tozuka | Oct 1999 | A |
5964749 | Eckhouse | Oct 1999 | A |
5967976 | Larsen | Oct 1999 | A |
5980561 | Kolen | Nov 1999 | A |
5986167 | Arteman | Nov 1999 | A |
5989286 | Owens | Nov 1999 | A |
5997530 | Nelson | Dec 1999 | A |
6017337 | Pira | Jan 2000 | A |
6023932 | Johnston et al. | Feb 2000 | A |
6032675 | Rubinsky et al. | Mar 2000 | A |
6039694 | Larson | Mar 2000 | A |
6041787 | Rubinsky et al. | Mar 2000 | A |
6047215 | McClure | Apr 2000 | A |
6049927 | Thomas et al. | Apr 2000 | A |
6051159 | Hao | Apr 2000 | A |
6071239 | Cribbs | Jun 2000 | A |
6074415 | Der Ovanesian | Jun 2000 | A |
6093230 | Johnson, III | Jul 2000 | A |
6102885 | Bass | Aug 2000 | A |
6104952 | Tu | Aug 2000 | A |
6104959 | Spertell | Aug 2000 | A |
6106517 | Zupkas | Aug 2000 | A |
6113558 | Rosenschein | Sep 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6113626 | Clifton | Sep 2000 | A |
6120519 | Weber | Sep 2000 | A |
6139544 | Mikus | Oct 2000 | A |
6150148 | Nanda | Nov 2000 | A |
6151735 | Koby et al. | Nov 2000 | A |
6152952 | Owens | Nov 2000 | A |
6171301 | Nelson | Jan 2001 | B1 |
6180867 | Hedengren et al. | Jan 2001 | B1 |
6181867 | Kenner et al. | Jan 2001 | B1 |
6200281 | Frajdenrajch | Mar 2001 | B1 |
6226996 | Weber | May 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6264649 | Whitcroft et al. | Jul 2001 | B1 |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6290988 | Van Vilsteren et al. | Sep 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6311497 | Chung | Nov 2001 | B1 |
6312453 | Stefanile | Nov 2001 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6354297 | Eiseman | Mar 2002 | B1 |
6357907 | Cleveland et al. | Mar 2002 | B1 |
6375673 | Clifton | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6401722 | Karg | Jun 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6413255 | Stern et al. | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6426445 | Young et al. | Jul 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6430956 | Haas et al. | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6438954 | Goetz | Aug 2002 | B1 |
6438964 | Giblin | Aug 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6458888 | Hood et al. | Oct 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6471693 | Carroll et al. | Oct 2002 | B1 |
6475211 | Chess | Nov 2002 | B2 |
6478811 | Dobak, III | Nov 2002 | B1 |
6494844 | Van Bladel | Dec 2002 | B1 |
6497721 | Ginsburg | Dec 2002 | B2 |
6508831 | Kushnir | Jan 2003 | B1 |
6514244 | Pope | Feb 2003 | B2 |
6519964 | Bieberich | Feb 2003 | B2 |
6523354 | Tolbert | Feb 2003 | B1 |
6527765 | Kelman | Mar 2003 | B2 |
6527798 | Ginsburg | Mar 2003 | B2 |
6544248 | Bass | Apr 2003 | B1 |
6547811 | Becker | Apr 2003 | B1 |
6548297 | Kuri-Harcuch et al. | Apr 2003 | B1 |
6551255 | Van Bladel | Apr 2003 | B2 |
6551341 | Boylan | Apr 2003 | B2 |
6551348 | Blalock et al. | Apr 2003 | B1 |
6551349 | Lasheras et al. | Apr 2003 | B2 |
6569189 | Augustine | May 2003 | B1 |
6585652 | Lang | Jul 2003 | B2 |
6592577 | Abboud | Jul 2003 | B2 |
6605080 | Altshuler et al. | Aug 2003 | B1 |
6607498 | Eshel | Aug 2003 | B2 |
6620187 | Carson | Sep 2003 | B2 |
6620188 | Ginsburg | Sep 2003 | B1 |
6620189 | Machold | Sep 2003 | B1 |
6623430 | Slayton et al. | Sep 2003 | B1 |
6626854 | Friedman | Sep 2003 | B2 |
6632219 | Baranov | Oct 2003 | B1 |
6635053 | Lalonde et al. | Oct 2003 | B1 |
6643535 | Damasco | Nov 2003 | B2 |
6645162 | Friedman | Nov 2003 | B2 |
6645229 | Matsmura | Nov 2003 | B2 |
6645232 | Carson | Nov 2003 | B2 |
6648904 | Altshuler et al. | Nov 2003 | B2 |
6656208 | Grahn | Dec 2003 | B2 |
6660027 | Gruszecki | Dec 2003 | B2 |
6662054 | Kreindel | Dec 2003 | B2 |
6682550 | Clifton | Jan 2004 | B2 |
6685731 | Kushnir | Feb 2004 | B2 |
6694170 | Mikus | Feb 2004 | B1 |
6695874 | Machold | Feb 2004 | B2 |
6697670 | Chorneky | Feb 2004 | B2 |
6699237 | Weber | Mar 2004 | B2 |
6699266 | Lachenbruch et al. | Mar 2004 | B2 |
6699267 | Voorhees | Mar 2004 | B2 |
6718785 | Bieberich | Apr 2004 | B2 |
6741895 | Gafni et al. | May 2004 | B1 |
6743222 | Durkin | Jun 2004 | B2 |
6746474 | Saadat | Jun 2004 | B2 |
6749624 | Knowlton | Jun 2004 | B2 |
6764493 | Weber | Jul 2004 | B1 |
6764502 | Bieberich | Jul 2004 | B2 |
6789545 | Littrup | Sep 2004 | B2 |
6795728 | Chornenky et al. | Sep 2004 | B2 |
6820961 | Johnson, III | Nov 2004 | B2 |
6821274 | McHale et al. | Nov 2004 | B2 |
6840955 | Ein | Jan 2005 | B2 |
6849075 | Bertolero | Feb 2005 | B2 |
6878144 | Altshuler et al. | Apr 2005 | B2 |
6889090 | Kreindel | May 2005 | B2 |
6892099 | Jaafar | May 2005 | B2 |
6904956 | Noel | Jun 2005 | B2 |
6918903 | Bass | Jul 2005 | B2 |
6927316 | Faries | Aug 2005 | B1 |
6942022 | Blangetti et al. | Sep 2005 | B2 |
6945942 | Van Bladel | Sep 2005 | B2 |
6948903 | Ablabutyan | Sep 2005 | B2 |
6969399 | Schock | Nov 2005 | B2 |
7005558 | Johnansson et al. | Feb 2006 | B1 |
7006874 | Knowlton | Feb 2006 | B2 |
7022121 | Stern et al. | Apr 2006 | B2 |
7037326 | Lee | May 2006 | B2 |
7054685 | Dimmer | May 2006 | B2 |
7060061 | Altshuler et al. | Jun 2006 | B2 |
7077858 | Fletcher et al. | Jul 2006 | B2 |
7081111 | Svaasand et al. | Jul 2006 | B2 |
7083612 | Littrup | Aug 2006 | B2 |
7096204 | Chen | Aug 2006 | B1 |
7112712 | Ancell | Sep 2006 | B1 |
7115123 | Knowlton | Oct 2006 | B2 |
7141049 | Stern et al. | Nov 2006 | B2 |
7183360 | Daniel et al. | Feb 2007 | B2 |
7189252 | Krueger | Mar 2007 | B2 |
7192426 | Baust | Mar 2007 | B2 |
7204832 | Altshuler et al. | Apr 2007 | B2 |
7220778 | Anderson et al. | May 2007 | B2 |
7229436 | Stern et al. | Jun 2007 | B2 |
7258674 | Cribbs | Aug 2007 | B2 |
7267675 | Stern et al. | Sep 2007 | B2 |
7276058 | Altshuler et al. | Oct 2007 | B2 |
7318821 | Lalonde et al. | Jan 2008 | B2 |
7331951 | Eshel | Feb 2008 | B2 |
7347855 | Eshel | Mar 2008 | B2 |
7367341 | Anderson et al. | May 2008 | B2 |
7532201 | Quistgaard et al. | May 2009 | B2 |
7572268 | Babaev | Aug 2009 | B2 |
7604632 | Howlett | Oct 2009 | B2 |
7613523 | Eggers | Nov 2009 | B2 |
7615016 | Barthe | Nov 2009 | B2 |
7713266 | Elkins et al. | May 2010 | B2 |
7780656 | Tankovich | Aug 2010 | B2 |
7799018 | Goulko | Sep 2010 | B2 |
7824437 | Saunders | Nov 2010 | B1 |
7828831 | Tanhehco | Nov 2010 | B1 |
7850683 | Elkins et al. | Dec 2010 | B2 |
7854754 | Ting et al. | Dec 2010 | B2 |
7862558 | Elkins et al. | Jan 2011 | B2 |
RE42277 | Jaafar | Apr 2011 | E |
7938824 | Chornenky et al. | May 2011 | B2 |
7959657 | Harsy et al. | Jun 2011 | B1 |
7963959 | Da Silva | Jun 2011 | B2 |
7967763 | Deem | Jun 2011 | B2 |
7993330 | Goulko | Aug 2011 | B2 |
7998137 | Elkins et al. | Aug 2011 | B2 |
RE42835 | Chornenky et al. | Oct 2011 | E |
RE43009 | Chornenky et al. | Dec 2011 | E |
8133180 | Slayton et al. | Mar 2012 | B2 |
8133191 | Rosenberg et al. | Mar 2012 | B2 |
8192474 | Levinson et al. | Jun 2012 | B2 |
8246611 | Paithankar | Aug 2012 | B2 |
8275442 | Allison | Sep 2012 | B2 |
8285390 | Levinson et al. | Oct 2012 | B2 |
8333700 | Barthe | Dec 2012 | B1 |
8337539 | Ting et al. | Dec 2012 | B2 |
8366622 | Slayton et al. | Feb 2013 | B2 |
8372130 | Young et al. | Feb 2013 | B2 |
8397518 | Vistakula | Mar 2013 | B1 |
8414631 | Quisenberry et al. | Apr 2013 | B2 |
8433400 | Prushinskaya | Apr 2013 | B2 |
8506486 | Slayton et al. | Aug 2013 | B2 |
8523775 | Barthe | Sep 2013 | B2 |
8523791 | Castel | Sep 2013 | B2 |
8523927 | Levinson et al. | Sep 2013 | B2 |
8535228 | Slayton et al. | Sep 2013 | B2 |
8603073 | Allison | Dec 2013 | B2 |
8636665 | Slayton et al. | Jan 2014 | B2 |
8641622 | Barthe | Feb 2014 | B2 |
8663112 | Slayton et al. | Mar 2014 | B2 |
8672848 | Slayton et al. | Mar 2014 | B2 |
8676332 | Fahey | Mar 2014 | B2 |
8690778 | Slayton et al. | Apr 2014 | B2 |
8690779 | Slayton et al. | Apr 2014 | B2 |
8690780 | Slayton et al. | Apr 2014 | B2 |
8702774 | Baker et al. | Apr 2014 | B2 |
8758215 | Legendre et al. | Jun 2014 | B2 |
8764693 | Graham et al. | Jul 2014 | B1 |
8834547 | Anderson et al. | Sep 2014 | B2 |
10383787 | Rosen | Aug 2019 | B2 |
20010005791 | Ginsburg | Jun 2001 | A1 |
20010007952 | Shimizu | Jul 2001 | A1 |
20010023364 | Ahn | Sep 2001 | A1 |
20010031459 | Fahy et al. | Oct 2001 | A1 |
20010039439 | Elkins et al. | Nov 2001 | A1 |
20010045104 | Bailey et al. | Nov 2001 | A1 |
20010047196 | Ginsburg | Nov 2001 | A1 |
20020026226 | Ein | Feb 2002 | A1 |
20020032473 | Kushnir | Mar 2002 | A1 |
20020042607 | Palmer et al. | Apr 2002 | A1 |
20020049483 | Knowlton | Apr 2002 | A1 |
20020058975 | Bieberich | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020068338 | Nanda | Jun 2002 | A1 |
20020082668 | Ingman | Jun 2002 | A1 |
20020103520 | Latham | Aug 2002 | A1 |
20020107558 | Clifton | Aug 2002 | A1 |
20020117293 | Campbell | Aug 2002 | A1 |
20020120315 | Furuno et al. | Aug 2002 | A1 |
20020128648 | Weber | Sep 2002 | A1 |
20020151830 | Kahn | Oct 2002 | A1 |
20020151887 | Stern et al. | Oct 2002 | A1 |
20020156509 | Cheung | Oct 2002 | A1 |
20020188286 | Quijano | Dec 2002 | A1 |
20020198518 | Mikus | Dec 2002 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030044764 | Soane et al. | Mar 2003 | A1 |
20030055414 | Altshuler et al. | Mar 2003 | A1 |
20030062040 | Lurie et al. | Apr 2003 | A1 |
20030069618 | Smith et al. | Apr 2003 | A1 |
20030077326 | Newton | Apr 2003 | A1 |
20030077329 | Kipp et al. | Apr 2003 | A1 |
20030079488 | Bieberich | May 2003 | A1 |
20030100936 | Altshuler et al. | May 2003 | A1 |
20030109908 | Lachenbruch et al. | Jun 2003 | A1 |
20030109910 | Lachenbruch et al. | Jun 2003 | A1 |
20030109911 | Lachenbruch et al. | Jun 2003 | A1 |
20030114885 | Nova | Jun 2003 | A1 |
20030120268 | Bertolero | Jun 2003 | A1 |
20030125649 | McIntosh et al. | Jul 2003 | A1 |
20030187488 | Kreindel | Oct 2003 | A1 |
20030199226 | Sommer et al. | Oct 2003 | A1 |
20030199859 | Altshuler et al. | Oct 2003 | A1 |
20030220594 | Halvorson | Nov 2003 | A1 |
20030220635 | Knowlton | Nov 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20030236487 | Knowlton | Dec 2003 | A1 |
20040002705 | Knowlton | Jan 2004 | A1 |
20040006328 | Anderson et al. | Jan 2004 | A1 |
20040009936 | Tang et al. | Jan 2004 | A1 |
20040024437 | Machold | Feb 2004 | A1 |
20040030332 | Knowlton | Feb 2004 | A1 |
20040034341 | Altshuler et al. | Feb 2004 | A1 |
20040039312 | Hillstead et al. | Feb 2004 | A1 |
20040044384 | Leber et al. | Mar 2004 | A1 |
20040049178 | Abboud | Mar 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040074629 | Noel | Apr 2004 | A1 |
20040077977 | Ella | Apr 2004 | A1 |
20040082886 | Timpson | Apr 2004 | A1 |
20040093042 | Altshuler et al. | May 2004 | A1 |
20040104012 | Zhou | Jun 2004 | A1 |
20040106867 | Eshel | Jun 2004 | A1 |
20040133251 | Altshuler et al. | Jul 2004 | A1 |
20040162596 | Altshuler et al. | Aug 2004 | A1 |
20040176667 | Mihai et al. | Sep 2004 | A1 |
20040186535 | Knowlton | Sep 2004 | A1 |
20040199226 | Shadduck | Oct 2004 | A1 |
20040206365 | Knowlton | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040210287 | Greene | Oct 2004 | A1 |
20040215294 | Littrup | Oct 2004 | A1 |
20040249427 | Nabilsi et al. | Dec 2004 | A1 |
20040259855 | Anderson et al. | Dec 2004 | A1 |
20040260209 | Ella | Dec 2004 | A1 |
20040260210 | Ella | Dec 2004 | A1 |
20040260211 | Maalouf | Dec 2004 | A1 |
20040267339 | Yon | Dec 2004 | A1 |
20050010197 | Lau et al. | Jan 2005 | A1 |
20050033957 | Enokida | Feb 2005 | A1 |
20050049526 | Baer | Mar 2005 | A1 |
20050049543 | Anderson et al. | Mar 2005 | A1 |
20050049661 | Koffroth | Mar 2005 | A1 |
20050113725 | Masuda | May 2005 | A1 |
20050143781 | Carbunaru | Jun 2005 | A1 |
20050145372 | Noel | Jul 2005 | A1 |
20050149153 | Nakase | Jul 2005 | A1 |
20050154314 | Quistgaard et al. | Jul 2005 | A1 |
20050154431 | Quistgaard et al. | Jul 2005 | A1 |
20050159986 | Breeland et al. | Jul 2005 | A1 |
20050177075 | Meunier et al. | Aug 2005 | A1 |
20050182462 | Chornenky et al. | Aug 2005 | A1 |
20050187495 | Quistgaard et al. | Aug 2005 | A1 |
20050187597 | Vanderschuit | Aug 2005 | A1 |
20050203446 | Takashima | Sep 2005 | A1 |
20050215987 | Slatkine | Sep 2005 | A1 |
20050222565 | Manstein | Oct 2005 | A1 |
20050251117 | Anderson et al. | Nov 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20050261753 | Littrup | Nov 2005 | A1 |
20050277859 | Carlsmith et al. | Dec 2005 | A1 |
20050283144 | Shiono et al. | Dec 2005 | A1 |
20060030778 | Mendlein et al. | Feb 2006 | A1 |
20060035380 | Saint-Leger | Feb 2006 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060041704 | Choie | Feb 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060079852 | Bubb et al. | Apr 2006 | A1 |
20060094988 | Tosaya | May 2006 | A1 |
20060106836 | Masugi | May 2006 | A1 |
20060111613 | Boutillette et al. | May 2006 | A1 |
20060122509 | Desilets | Jun 2006 | A1 |
20060189964 | Anderson et al. | Aug 2006 | A1 |
20060195168 | Dunbar | Aug 2006 | A1 |
20060200063 | Munro et al. | Sep 2006 | A1 |
20060206040 | Greenberg | Sep 2006 | A1 |
20060206110 | Knowlton | Sep 2006 | A1 |
20060211958 | Rosenberg et al. | Sep 2006 | A1 |
20060234899 | Nekmard et al. | Oct 2006 | A1 |
20060259102 | Slatkine | Nov 2006 | A1 |
20060265032 | Hennings | Nov 2006 | A1 |
20060270745 | Hunt et al. | Nov 2006 | A1 |
20060293734 | Scott et al. | Dec 2006 | A1 |
20070010811 | Stern et al. | Jan 2007 | A1 |
20070010861 | Anderson et al. | Jan 2007 | A1 |
20070032561 | Lin et al. | Feb 2007 | A1 |
20070038156 | Rosenberg et al. | Feb 2007 | A1 |
20070055156 | Desilets | Mar 2007 | A1 |
20070055173 | DeLonzor | Mar 2007 | A1 |
20070055179 | Deem | Mar 2007 | A1 |
20070055180 | Deem | Mar 2007 | A1 |
20070055181 | Deem et al. | Mar 2007 | A1 |
20070073367 | Jones | Mar 2007 | A1 |
20070078502 | Weber | Apr 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070106342 | Schumann | May 2007 | A1 |
20070129714 | Elkins et al. | Jun 2007 | A1 |
20070135876 | Weber | Jun 2007 | A1 |
20070141265 | Thomson | Jun 2007 | A1 |
20070179482 | Anderson et al. | Aug 2007 | A1 |
20070198071 | Ting et al. | Aug 2007 | A1 |
20070219540 | Masotti | Sep 2007 | A1 |
20070239075 | Rosenberg et al. | Oct 2007 | A1 |
20070239150 | Zvuloni | Oct 2007 | A1 |
20070249519 | Guha et al. | Oct 2007 | A1 |
20070255187 | Branch | Nov 2007 | A1 |
20070255274 | Stern et al. | Nov 2007 | A1 |
20070255362 | Levinson et al. | Nov 2007 | A1 |
20070265585 | Joshi | Nov 2007 | A1 |
20070265614 | Stern et al. | Nov 2007 | A1 |
20070270925 | Levinson | Nov 2007 | A1 |
20070282249 | Quisenberry et al. | Dec 2007 | A1 |
20070282318 | Spooner | Dec 2007 | A1 |
20080014627 | Merchant | Jan 2008 | A1 |
20080046047 | Jacobs | Feb 2008 | A1 |
20080058784 | Manstein et al. | Mar 2008 | A1 |
20080077201 | Levinson et al. | Mar 2008 | A1 |
20080077202 | Levinson et al. | Mar 2008 | A1 |
20080077211 | Levinson et al. | Mar 2008 | A1 |
20080097207 | Cai et al. | Apr 2008 | A1 |
20080139901 | Altshuler et al. | Jun 2008 | A1 |
20080140061 | Toubia | Jun 2008 | A1 |
20080140371 | Warner | Jun 2008 | A1 |
20080161892 | Mercuro et al. | Jul 2008 | A1 |
20080183164 | Elkins et al. | Jul 2008 | A1 |
20080188915 | Mills | Aug 2008 | A1 |
20080248554 | Merchant | Oct 2008 | A1 |
20080269851 | Deem | Oct 2008 | A1 |
20080287839 | Rosen | Nov 2008 | A1 |
20080300529 | Reinstein | Dec 2008 | A1 |
20080312651 | Pope | Dec 2008 | A1 |
20090012434 | Andersn | Jan 2009 | A1 |
20090018623 | Levinson et al. | Jan 2009 | A1 |
20090018624 | Levinson et al. | Jan 2009 | A1 |
20090018625 | Levinson et al. | Jan 2009 | A1 |
20090018626 | Levinson et al. | Jan 2009 | A1 |
20090018627 | Levinson et al. | Jan 2009 | A1 |
20090024023 | Welches | Jan 2009 | A1 |
20090076488 | Welches | Mar 2009 | A1 |
20090112134 | Avni | Apr 2009 | A1 |
20090118722 | Ebbers | May 2009 | A1 |
20090149929 | Levinson et al. | Jun 2009 | A1 |
20090149930 | Schneck | Jun 2009 | A1 |
20090171253 | Davenport | Jul 2009 | A1 |
20090171334 | Elkins et al. | Jul 2009 | A1 |
20090221938 | Rosenberg et al. | Sep 2009 | A1 |
20090226424 | Hsu | Sep 2009 | A1 |
20090276018 | Brader | Nov 2009 | A1 |
20090281464 | Cioanta | Nov 2009 | A1 |
20090299234 | Cho et al. | Dec 2009 | A1 |
20090306749 | Mulindwa | Dec 2009 | A1 |
20090312676 | Rousso | Dec 2009 | A1 |
20090312693 | Thapliyal | Dec 2009 | A1 |
20090326621 | El-Galley | Dec 2009 | A1 |
20100015190 | Hassler | Jan 2010 | A1 |
20100028969 | Mueller et al. | Feb 2010 | A1 |
20100030306 | Edelman | Feb 2010 | A1 |
20100036295 | Altshuler et al. | Feb 2010 | A1 |
20100042087 | Goldboss et al. | Feb 2010 | A1 |
20100049178 | Deem | Feb 2010 | A1 |
20100081971 | Allison | Apr 2010 | A1 |
20100087806 | Da Silva | Apr 2010 | A1 |
20100152824 | Allison | Jun 2010 | A1 |
20100168726 | Brookman | Jul 2010 | A1 |
20100179531 | Nebrigic et al. | Jul 2010 | A1 |
20100198064 | Perl | Aug 2010 | A1 |
20100217349 | Fahey | Aug 2010 | A1 |
20100241023 | Gilbert | Sep 2010 | A1 |
20100268220 | Johnson, III | Oct 2010 | A1 |
20100280582 | Baker et al. | Nov 2010 | A1 |
20110009860 | Chornenky et al. | Jan 2011 | A1 |
20110040235 | Castel | Feb 2011 | A1 |
20110040299 | Kim | Feb 2011 | A1 |
20110046523 | Altshuler et al. | Feb 2011 | A1 |
20110060323 | Baust | Mar 2011 | A1 |
20110066083 | Tosaya | Mar 2011 | A1 |
20110066216 | Ting et al. | Mar 2011 | A1 |
20110077557 | Wing | Mar 2011 | A1 |
20110077723 | Parish et al. | Mar 2011 | A1 |
20110112405 | Barthe | May 2011 | A1 |
20110112520 | Kreindel | May 2011 | A1 |
20110144630 | Loeb | Jun 2011 | A1 |
20110144631 | Elkins et al. | Jun 2011 | A1 |
20110152849 | Baust | Jun 2011 | A1 |
20110172651 | Altshuler et al. | Jul 2011 | A1 |
20110189129 | Qiu | Aug 2011 | A1 |
20110196395 | Maschke | Aug 2011 | A1 |
20110196438 | Mnozil et al. | Aug 2011 | A1 |
20110202048 | Nebrigic et al. | Aug 2011 | A1 |
20110238050 | Allison | Sep 2011 | A1 |
20110238051 | Levinson et al. | Sep 2011 | A1 |
20110257642 | Griggs | Oct 2011 | A1 |
20110288537 | Halaka | Nov 2011 | A1 |
20110300079 | Martens | Dec 2011 | A1 |
20110301585 | Goulko | Dec 2011 | A1 |
20110313411 | Anderson et al. | Dec 2011 | A1 |
20110313412 | Kim | Dec 2011 | A1 |
20120010609 | Deem | Jan 2012 | A1 |
20120016239 | Barthe | Jan 2012 | A1 |
20120022518 | Levinson et al. | Jan 2012 | A1 |
20120022622 | Johnson, III | Jan 2012 | A1 |
20120035475 | Barthe | Feb 2012 | A1 |
20120035476 | Barthe | Feb 2012 | A1 |
20120046547 | Barthe | Feb 2012 | A1 |
20120053458 | Barthe | Mar 2012 | A1 |
20120065629 | Elkins et al. | Mar 2012 | A1 |
20120083862 | Altshuler et al. | Apr 2012 | A1 |
20120101549 | Schumann | Apr 2012 | A1 |
20120109041 | Munz | May 2012 | A1 |
20120158100 | Schomacker | Jun 2012 | A1 |
20120209363 | Williams | Aug 2012 | A1 |
20120233736 | Tepper et al. | Sep 2012 | A1 |
20120239123 | Weber | Sep 2012 | A1 |
20120253416 | Erez | Oct 2012 | A1 |
20120259322 | Fourkas | Oct 2012 | A1 |
20120277674 | Clark, III | Nov 2012 | A1 |
20120310232 | Erez | Dec 2012 | A1 |
20130018236 | Altshuler et al. | Jan 2013 | A1 |
20130019374 | Schwartz | Jan 2013 | A1 |
20130066309 | Levinson et al. | Mar 2013 | A1 |
20130073017 | Liu | Mar 2013 | A1 |
20130079684 | Rosen | Mar 2013 | A1 |
20130116758 | Levinson et al. | May 2013 | A1 |
20130116759 | Levinson et al. | May 2013 | A1 |
20130150844 | Deem | Jun 2013 | A1 |
20130158440 | Allison | Jun 2013 | A1 |
20130158636 | Ting et al. | Jun 2013 | A1 |
20130166003 | Johnson | Jun 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130238062 | Ron | Sep 2013 | A1 |
20130245507 | Khorassani | Sep 2013 | A1 |
20130253384 | Anderson et al. | Sep 2013 | A1 |
20130253493 | Anderson et al. | Sep 2013 | A1 |
20130253494 | Anderson et al. | Sep 2013 | A1 |
20130253495 | Anderson et al. | Sep 2013 | A1 |
20130253496 | Anderson et al. | Sep 2013 | A1 |
20130303904 | Barthe | Nov 2013 | A1 |
20130303905 | Barthe | Nov 2013 | A1 |
20130331914 | Lee | Dec 2013 | A1 |
20140005759 | Fahey | Jan 2014 | A1 |
20140005760 | Levinson et al. | Jan 2014 | A1 |
20140067025 | Levinson et al. | Mar 2014 | A1 |
20140142469 | Britva | May 2014 | A1 |
20140200487 | Ramdas | Jul 2014 | A1 |
20140200488 | Seo | Jul 2014 | A1 |
20140222121 | Spence | Aug 2014 | A1 |
20140277219 | Nanda | Sep 2014 | A1 |
20140277302 | Weber | Sep 2014 | A1 |
20140277303 | Biser et al. | Sep 2014 | A1 |
20140303697 | Anderson et al. | Oct 2014 | A1 |
20150209174 | Abreu | Jul 2015 | A1 |
20150216719 | DeBenedictis et al. | Aug 2015 | A1 |
20150216720 | DeBenedictis et al. | Aug 2015 | A1 |
20150216816 | O'Neil et al. | Aug 2015 | A1 |
20150223975 | Anderson et al. | Aug 2015 | A1 |
20150283022 | Lee et al. | Oct 2015 | A1 |
20150328077 | Levinson et al. | Nov 2015 | A1 |
20150335468 | Rose | Nov 2015 | A1 |
20150342780 | Levinson et al. | Dec 2015 | A1 |
20160051308 | Pennybacker | Feb 2016 | A1 |
20160051401 | Yee | Feb 2016 | A1 |
20160135985 | Anderson et al. | May 2016 | A1 |
20160324684 | Levinson et al. | Nov 2016 | A1 |
20170007309 | DeBenedictis et al. | Jan 2017 | A1 |
20170079833 | Frangineas, Jr. et al. | Mar 2017 | A1 |
20170105869 | Frangineas, Jr. et al. | Apr 2017 | A1 |
20170165105 | Anderson et al. | Jun 2017 | A1 |
20170196731 | DeBenedictis et al. | Jul 2017 | A1 |
20170239079 | Root et al. | Aug 2017 | A1 |
20170325992 | DeBenedictis et al. | Nov 2017 | A1 |
20170325993 | Jimenez Lozano et al. | Nov 2017 | A1 |
20170326042 | Zeng et al. | Nov 2017 | A1 |
20170326346 | Jimenez Lozano et al. | Nov 2017 | A1 |
20180185081 | O'Neil et al. | Jul 2018 | A1 |
20180185189 | Weber | Jul 2018 | A1 |
20180263677 | Hilton | Sep 2018 | A1 |
20180271767 | Jimenez Lozano | Sep 2018 | A1 |
20180310950 | Yee | Nov 2018 | A1 |
Number | Date | Country |
---|---|---|
2011253768 | Jun 2012 | AU |
2441489 | Mar 2005 | CA |
2585214 | Oct 2007 | CA |
333982 | Nov 1958 | CH |
86200604 | Oct 1987 | CN |
2514795 | Oct 2002 | CN |
2514811 | Oct 2002 | CN |
1511503 | Jul 2004 | CN |
1741777 | Mar 2006 | CN |
1817990 | Aug 2006 | CN |
2843367 | Dec 2006 | CN |
2850584 | Dec 2006 | CN |
2850585 | Dec 2006 | CN |
200970265 | Nov 2007 | CN |
101259329 | Sep 2008 | CN |
101309657 | Nov 2008 | CN |
532976 | Sep 1931 | DE |
2851602 | Jun 1980 | DE |
4213584 | Nov 1992 | DE |
4224595 | Jan 1994 | DE |
4238291 | May 1994 | DE |
4445627 | Jun 1996 | DE |
19800416 | Jul 1999 | DE |
0263069 | Apr 1988 | EP |
02630692 | Apr 1988 | EP |
0397043 | Nov 1990 | EP |
0406244 | Jan 1991 | EP |
560309 | Sep 1993 | EP |
0598824 | Jun 1994 | EP |
1030611 | Aug 2000 | EP |
1201266 | May 2002 | EP |
1568395 | Aug 2005 | EP |
1627662 | Feb 2006 | EP |
2260801 | Dec 2010 | EP |
2289598 | Mar 2011 | EP |
2527005 | Nov 2012 | EP |
1991315 | Nov 2013 | EP |
2010938 | Dec 1989 | ES |
854937 | Apr 1940 | FR |
2744358 | Aug 1997 | FR |
2745935 | Sep 1997 | FR |
2767476 | Feb 1999 | FR |
2776920 | Oct 1999 | FR |
2789893 | Aug 2000 | FR |
2792828 | Nov 2000 | FR |
2805989 | Sep 2001 | FR |
2844996 | Apr 2004 | FR |
387960 | Feb 1933 | GB |
1417989 | Dec 1975 | GB |
2120944 | Dec 1983 | GB |
2202447 | Sep 1988 | GB |
2248183 | Apr 1992 | GB |
2263872 | Aug 1993 | GB |
2286660 | Aug 1995 | GB |
2323659 | Sep 1998 | GB |
58187454 | Nov 1983 | JP |
S6094113 | May 1985 | JP |
63076895 | Apr 1988 | JP |
01223961 | Sep 1989 | JP |
03051964 | Mar 1991 | JP |
3259975 | Nov 1991 | JP |
4093597 | Mar 1992 | JP |
06261933 | Sep 1994 | JP |
6282977 | Oct 1994 | JP |
7194666 | Aug 1995 | JP |
7268274 | Oct 1995 | JP |
2000503154 | Jan 1997 | JP |
09164163 | Jun 1997 | JP |
10216169 | Aug 1998 | JP |
10223961 | Aug 1998 | JP |
2002543668 | Apr 2000 | JP |
3065657 | Jul 2000 | JP |
2001046416 | Feb 2001 | JP |
2002125993 | May 2002 | JP |
2002224051 | Aug 2002 | JP |
2002282295 | Oct 2002 | JP |
2002290397 | Oct 2002 | JP |
2003190201 | Jul 2003 | JP |
2004013600 | Jan 2004 | JP |
2006520949 | Jan 2004 | JP |
2004073812 | Mar 2004 | JP |
2004159666 | Jun 2004 | JP |
2005039790 | Feb 2005 | JP |
200565984 | Mar 2005 | JP |
2005110755 | Apr 2005 | JP |
2005509977 | Apr 2005 | JP |
3655280 | Jun 2005 | JP |
2005520608 | Jul 2005 | JP |
2005237908 | Sep 2005 | JP |
2005296042 | Oct 2005 | JP |
2005323716 | Nov 2005 | JP |
2008323716 | Nov 2005 | JP |
2006026001 | Feb 2006 | JP |
2006094988 | Apr 2006 | JP |
2006130055 | May 2006 | JP |
2007270459 | Oct 2007 | JP |
2008532591 | Aug 2008 | JP |
2009515232 | Apr 2009 | JP |
2009189757 | Aug 2009 | JP |
200173222 | Dec 1999 | KR |
1020040094508 | Nov 2004 | KR |
102006134245 | Dec 2006 | KR |
20090000258 | Jan 2009 | KR |
1020130043299 | Apr 2013 | KR |
1020140038165 | Mar 2014 | KR |
2036667 | Jun 1995 | RU |
532976 | Nov 1978 | SU |
0476644 | Feb 2002 | TW |
WO1985003216 | Aug 1985 | WO |
WO9114417 | Oct 1991 | WO |
WO9404116 | Mar 1994 | WO |
WO9509596 | Apr 1995 | WO |
WO9623447 | Aug 1996 | WO |
WO9626693 | Sep 1996 | WO |
WO9636293 | Nov 1996 | WO |
WO9637158 | Nov 1996 | WO |
WO9704832 | Feb 1997 | WO |
WO9705828 | Feb 1997 | WO |
9722262 | Jun 1997 | WO |
WO9722262 | Jun 1997 | WO |
WO9724088 | Jul 1997 | WO |
WO9725798 | Jul 1997 | WO |
WO1997025798 | Jul 1997 | WO |
WO9748440 | Dec 1997 | WO |
WO1998002123 | Jan 1998 | WO |
WO9829134 | Jul 1998 | WO |
WO9831321 | Jul 1998 | WO |
WO9841156 | Sep 1998 | WO |
WO9841157 | Sep 1998 | WO |
WO9909928 | Mar 1999 | WO |
WO9916502 | Apr 1999 | WO |
WO9938469 | Aug 1999 | WO |
WO9949937 | Oct 1999 | WO |
WO0044346 | Aug 2000 | WO |
WO0044349 | Aug 2000 | WO |
WO0065770 | Nov 2000 | WO |
WO0067685 | Nov 2000 | WO |
WO2000067685 | Nov 2000 | WO |
WO0100269 | Jan 2001 | WO |
WO0113989 | Mar 2001 | WO |
WO2001014012 | Mar 2001 | WO |
WO0134048 | May 2001 | WO |
WO2001034048 | May 2001 | WO |
WO0205736 | Jan 2002 | WO |
0205736 | Jul 2002 | WO |
WO02102921 | Dec 2002 | WO |
WO03007859 | Jan 2003 | WO |
WO200307859 | Jan 2003 | WO |
WO03013334 | Feb 2003 | WO |
03078596 | Sep 2003 | WO |
WO03078596 | Sep 2003 | WO |
WO03079916 | Oct 2003 | WO |
WO04000098 | Dec 2003 | WO |
WO04080279 | Sep 2004 | WO |
WO2004090939 | Oct 2004 | WO |
WO20050033957 | Apr 2005 | WO |
WO05046540 | May 2005 | WO |
WO2005060354 | Jul 2005 | WO |
WO2005096979 | Oct 2005 | WO |
WO2005112807 | Dec 2005 | WO |
WO2005112815 | Dec 2005 | WO |
WO06066226 | Jun 2006 | WO |
WO2006066226 | Jun 2006 | WO |
WO2006094348 | Sep 2006 | WO |
WO20060106836 | Oct 2006 | WO |
WO06127467 | Nov 2006 | WO |
WO2006116603 | Nov 2006 | WO |
WO2006122136 | Nov 2006 | WO |
WO2007012083 | Jan 2007 | WO |
WO2007028975 | Mar 2007 | WO |
2007041642 | Apr 2007 | WO |
WO07041642 | Apr 2007 | WO |
WO2007093998 | Aug 2007 | WO |
WO2007101039 | Sep 2007 | WO |
WO2007127924 | Nov 2007 | WO |
WO2007145421 | Dec 2007 | WO |
WO2007145422 | Dec 2007 | WO |
WO2008006018 | Jan 2008 | WO |
WO2008039556 | Apr 2008 | WO |
WO2008039557 | Apr 2008 | WO |
WO2008055243 | May 2008 | WO |
WO2008094485 | Aug 2008 | WO |
WO2008143678 | Nov 2008 | WO |
WO2009011708 | Jan 2009 | WO |
WO2009026471 | Feb 2009 | WO |
WO2010077841 | Jul 2010 | WO |
WO2010127315 | Nov 2010 | WO |
WO2012012296 | Jan 2012 | WO |
WO2012103242 | Aug 2012 | WO |
WO2013013059 | Jan 2013 | WO |
WO2013075006 | May 2013 | WO |
WO2013075016 | May 2013 | WO |
WO2013190337 | Dec 2013 | WO |
WO2014151872 | Sep 2014 | WO |
WO2014191263 | Dec 2014 | WO |
WO2015117001 | Aug 2015 | WO |
WO2015117005 | Aug 2015 | WO |
WO2015117026 | Aug 2015 | WO |
WO2015117032 | Aug 2015 | WO |
WO2015117036 | Aug 2015 | WO |
WO2016028796 | Feb 2016 | WO |
WO2016048721 | Mar 2016 | WO |
Entry |
---|
“ThermaCool Monopolar Capacitive Radiofrequency, The One Choice for Nonablative Tissue Tightening and Contouring”, Thermage, Inc. Tech Brochure, Nov. 30, 2005, 8 pgs. |
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis,” Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages. |
Al-Sakere, B. “Tumor Ablation with Irreversible Electroporation,” PLoS One 2(11 ), Nov. 2007, 8 pages. |
Alster, T. et al., “Cellulite Treatment Using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic and Laser Therapy, vol. 7, 2005, pp. 81-85. |
Ardevol et al., “Cooling Rates of Tissue Samples During Freezing with Liquid Nitrogen,” Journal of Biochemical and Biophysical Methods, 27, 1993, pp. 77-86. |
Arena et al., “High-Frequency Irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction,” BioMedical Engineering OnLine 2011, 10:102, Nov. 21, 2011, 21 pgs. |
Becker, S. M. et al. “Local Temperature Rises Influence In Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model,” Journal of Biomechanical Engineering, vol. 129, Oct. 2007, pp. 712-721. |
Bohm et al., “Saline-enhanced radiofrequency ablation of breast tissue: an in vitro feasibility stud,” Invest Radiol, 2000, pp. 149-157, vol. 35—issue 3. |
Bondei et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Fourth Edition, vol. 1, Chapter 108, 1993, Section 16, pp. 1333-1334. |
Burge et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 1990, 27(2):153-163. |
Coban, “Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating early Histoloaic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, 304-308. |
Del Pino, M. E. et al. “Effect of Controlled Volumetric Tissue Heating with Radiofrequency on Cellulite and the Subcutaneous Tissue of the Buttocks and Thighs,” Journal of Drugs in Dermatology, vol. 5, Issue 8, Sep. 2006, pp. 714-722. |
Denski et al., “The Effects of Cooling no Experimental Free Flap Survival,” Brit J Plas Surg, 1980, pp. 353-360, vol. 33. |
Duck, F. A., Physical Properties of Tissue, Academic Press Ltd., chapters 4 & 5, 1990, pp. 73-165. |
Duncan et al., “Cold Panniculitis,” Arch. Derm., Dec. 1966, 94:722-24. |
Epstein et al., “Popsicle Panniculitis,” The New England Journal of Medicine, Apr. 23, 1970, 282(17):966-67. |
European Search Report, European Patent Application No. 07761461; Applicant: Zeltiq Aesthetics, Inc., dated Apr. 25, 2012, 9 pages. |
European Search Report, European Patent Application No. 10167756.5, Applicant: The General Hospital Corporation, dated Aug. 31, 2010, 6 pages. |
European Search Report, Supplement, European Patent Application No. 08798416.7, Applicant: Zeltiq Aesthetics, Inc., dated Jan. 12, 2012, 7 pages. |
European Search Report, Supplement, European Patent Application No. 09836823, Applicant: Zeltiq Aesthetics, Inc., dated May 15, 2012, 5 pages. |
Examination Report dated Dec. 14, 2010 in European Patent Application No. 07784124.5, 5 pages. |
Examination Report dated Jul. 27, 2016 in European Patent Application No. 15201268.8, 4 pages. |
Examination Report dated Jun. 3, 2013 in Canada Patent Application No. 2,687,344, 3 pages. |
Examination Report dated Mar. 13, 2014 in European Patent Application No. 07784124.5, 5 pages. |
Examination Report dated Mar. 19, 2012 in European Patent Application No. 07784124.5, 5 pages. |
Examination Report dated Mar. 19, 2013 in European Patent Application No. 07784124.5, 4 pages. |
Examination Report dated May 31, 2011 in Canada Patent Application No. 2,687,344, 3 pages. |
Examination Report dated Oct. 25, 2017 in European Patent Application No. 15201268.8, 7 pages. |
Extended European Search Report dated Nov. 16, 2013 in European Patent Application No. 15201268.8, 5 pages. |
Final Office Action: U.S. Appl. No. 10/391,221; dated Aug. 24, 2006 4 pages. |
Final Office Action: U.S. Appl. No. 11/750,953; dated Jul. 5, 2012 11 pages. |
Final Office Action; U.S. Appl. No. 11/016,196; dated Mar. 23, 2010, 12 pages. |
Final Office Action; U.S. Appl. No. 11/435,502; dated Mar. 29, 2010 11 pages. |
Final Office Action; U.S. Appl. No. 11/528,225; dated Dec. 29, 2010, 12 pages. |
Final Office Action; U.S. Appl. No. 11/558,046; dated Mar. 30, 2011, 17 pages. |
Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 19, 2012, 8 pages. |
First Examination Report dated Aug. 18, 2014 in Australian Patent Application No. 2012244313, 2 pages. |
First Examination Report dated Oct. 22, 2010 in Australian Patent Application No. 2007353791, 3 pages. |
Fournier, L. et al. “Lattice model for the kinetics of rupture of fluid bilayer membranes,” Physical Review, vol. 67, 2003, pp. 051908-1-051908-11. |
Gabriel, S. et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Physics in Medicine and Biology, vol. 41, 1996, pp. 2251-2269. |
Gage “Current Progress in Cryosurgery,” Cryobiology 25, 1988, pp. 483-486. |
Gatto, H. “Effects of thermal shocks on interleukin-1 levels and heat shock protein 72 (HSP72) expression in normal human keratinocytes,” PubMed, Arch Dermatol Res. 1992; 284(7): pp. 414-417 [Abstract]. |
Hale et al., “Influence of chronic heat exposure and prolonged food deprivation on execretion of mahnesium, phosphorus, calcium, hydrogen ion & ketones,” Aerosp Med, 1968, pp. 919-926, vol. 39—issue (9). |
Heller-Page et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, May 1988, vol. 18, No. 5, Pt 1, pp. 1003-1019. |
Hemmingsson et al., “Attenuation in Human Muscle and Fat Tissue in Vivo and in Vitro,” Acta RadioloQica Diaonosis, 1982, 23, 149-151. |
Henry et al., “Les Dermatoses Hivemales,” Rev Med Liege, 1999, 54: 11, 864-866. |
Hernan, P et al., “Study for the evaluation of the efficacy of Lipocryolysis (EEEL)”, Nov. 30, 2011. |
Hernan, R. P., “A Study to Evaluate the Action of Lipocryolysis”, 33(3) CryoLellers, 2012, pp. 176-180. |
Holland, DB. et al. “Cold Shock Induces The Synthesis of Stress Proteins in Human Keratinocytes,” PubMed Journal of Investigative Dermatology; 101(2): Aug. 1993, pp. 196-199. |
Holman et al., “Variation in Cryolesion Penetration Due to Probe Size and Tissue Thermal Conductivity,” The Annals of Thoracic Surgery, 1992, vol. 53, pp. 123-126. |
Hong et al., “Patterns of Ice Formation in Normal and Malignant Breast Tissue,” Cryobiology 31, 1994, pp. 109-120. |
Huang et al. “Comparative Proteomic Profiling of Murine Skin,” Journal of Investigative Dermatology, Department of Dermatology, Jul. 2003, pp. 51-64, vol. 121(1). |
International Search Report and Written Opinion for PCT/US2005/045988; Applicant: The General Hospital Corporation; dated Apr. 25, 2006, 14 pages. |
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages. |
International Search Report and Written Opinion for PCT/US2007/062508; Applicant: Juniper Medical Inc.; dated Jul. 20, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/064016; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/064017; Applicant: Juniper Medical, Inc.; dated Oct. 26, 2007, 16 pages. |
International Search Report and Written Opinion for PCT/US2007/064018; Applicant: Juniper Medical, Inc.; dated Jul. 26, 2007, 13 pages. |
International Search Report and Written Opinion for PCT/US2007/067638; Applicant: Juniper Medical, Inc.; dated Jan. 10, 2008, 11 pages. |
International Search Report and Written Opinion for PCT/US2007/069694; Applicant: Juniper Medical, Inc.; dated Nov. 23, 2007, 12 pages. |
International Search Report and Written Opinion for PCT/US2007/075935; Applicant: Zeltiq Aesthetics, Inc.; dated Apr. 10, 2008 (6 pages). |
International Search Report and Written Opinion for PCT/US2007/083255; Applicant: Zeltiq Aesthetics, Inc.; dated Aug. 11, 2008, 8 pages. |
International Search Report and Written Opinion for PCT/US2008/07393O; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 7, 2008, 10 pages. |
International Search Report and Written Opinion for PCT/US2009/058088; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 20, 2009, 14 pages. |
International Search Report and Written Opinion for PCT/US2009/067973; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 18, 2010, 10 pages. |
International Search Report and Written Opinion for PCT/US07/69694; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 23, 2007, 8 pages. |
International Search Report and Written Opinion for PCT/US2010/033290; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 25, 2011, 12 pages. |
International Search Report and Written Opinion for PCT/US2011/022112; Applicant: Zeltiq Aesthetics, Inc.; dated Mar. 18, 2011, 11 pages. |
International Search Report and Written Opinion for PCT/US2011/022444; Applicant: Zeltiq Aesthetics, Inc., dated Mar. 29, 2011, 14 pages. |
International Search Report for EP07758558.6; Applicant: Zeltiq Aesthetics, Inc.; dated Jul. 20, 2007, 4 pages. |
International Search Report for PCT/US2005/045988; (dated Apr. 25, 2006). |
Isambert, H. “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Physical Review Letters, vol. 80, No. 15, 1998, pp. 3404-3707. |
Jalian, H. R. et al., “Cryolipolysis: A Historical Perspective and Current Clinical Practice”, 32(1) Semin. Cutan. Med. Surg., 2013, pp. 31-34. |
Kellum, R. E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Archives of Dermatology, vol. 97, Apr. 1968, pp. 372-380. |
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Annals of the New York Academy of Sciences, vol. 967, 2002,pp. 500-505. |
Kundu, S. K. et al., “Breath Acetone Analyzer: Diagnostic Tool to Monitor Dietary Fat Loss,” Clinical Chemistry, vol. 39, Issue (1), 1993, pp. 87-92. |
Kundu, S. K. et al., “Novel Solid-Phase Assay of Ketone Bodies in Urine,” Clinical Chemistry, vol. 37, Issue (9), 1991, pp. 1565-1569. |
Kuroda, S. et al. “Thermal Distribution of Radio-Frequency Inductive Hyperthermia Using an Inductive Aperture-Type Applicator: Evaluation of the Effect of Tumor Size and Depth”, Medical and Biological Engineering and Computing, vol. 37, 1999, pp. 285-290. |
Laugier, P. et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryprobe,” The Society for Investigative Dermatology, Inc., vol. 111, No. 2, Aug. 1998, pp. 314-319. |
Levchenko et al., “Effect of Dehydration on Lipid Metabolism” Ukrainskii Biokhimicheskii Zhurnal, vol. 50, Issue 1, 1978, pp. 95-97. |
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refrigerated, and Frozen Specimens: An Animal Model,” Annals of Plastic Surgery, vol. 44, No. 5, May 2000, pp. 512-515. |
Liu, A. Y.-C. et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” Journal of Biological Chemistry, , 269(20), May 20, 1994, pp. 14768-14775. |
L'Vova, “Lipid levels and lipid peroxidation in frog tissues during hypothermia and hibernation,” WMJ, 1990, pp. 65-70, vol. 62—issue (1). |
Maize, J.C. “Panniculitis,” Cutaneous Pathology, Chapter 13, 1998, 327-344. |
Malcolm, G. T. et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” The American Journal of Clinical Nutrition, vol. 50, 1989, pp. 288-291. |
Manstein, D. et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis,” LasersSurg.Med 40:S20, 2008, p. 104. |
Manstein, D. et al. “Selective Cryolysis: A Novel Method of Non-lnvasive Fat Removal,” Lasers in Surgery and Medicine: The Official Journal of the ASLMS, vol. 40, No. 9, Nov. 2008, pp. 595-604. |
Mayoral “Case Reports: Skin Tightening with a Combined Unipolar and Bipolar Radiofrequency Device,” Journal of Drugs in Dermatology, 2007, pp. 212-215. |
Mazur, P. “Cryobiology: the Freezing of Biological Systems,” Science, 68, 1970, pp. 939-949. |
Merrill, T. “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010, 10 pages. |
Miklavcic, D. et al. “Electroporation-Based Technologies and Treatments,” The Journal of Membrane Biology (2010) 236:1-2, 2 pgs. |
Moschella, S. L. et al., “Diseases of the Subcutaneous Tissue,” in Dermatology, Second Edition, vol. 2, 1985 Chapter 19, Section II (W.B. Saunders Company, 1980) pp. 1169-1181. |
Murphy, J. V. et al., “Frostbite: Pathogenesis and Treatment” The Journal of Trauma Injury, Infection, and Critical Care, vol. 48, No. 1, Jan. 2000, pp. 171-178. |
Nagao, T. et al., “Dietary Diacylglycerol Suppresses Accumulation of Body Fat Compared to Triacylglycerol in Men a Double-Blind Controlled Trial,” The Journal of Nutrition, vol. 130, Issue (4), 2000, pp. 792-797. |
Nagle, W. A. et al. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures,” Cryobiology 27, 1990, pp. 439-451. |
Nagore, E. et al., “Lipoatrophia Semicircularis—a Traumatic Panniculitis: Report of Seven Cases and Review of the Literature,” Journal of the American Academy of Dermatology, vol. 39, Nov. 1998, pp. 879-881. |
Nanda, G.S. et al., “Studies on electroporation of thermally and chemically treated human erythrocytes,” Bioelectrochemistry and Bioenergetics, 34, 1994, pp. 129-134, 6 pgs. |
Narins, D.J. et al. “Non-Surgical Radiofrequency Facelift”, The Journal of Drugs in Dermatology, vol. 2, Issue 5, 2003, pp. 495-500. |
Nielsen, B. “Thermoregulation in Rest and Exercise,” Acta Physiologica Scandinavica Suppiementum, vol. 323 (Copenhagen 1969), pp. 7-74. |
Nishikawa, H. et al. “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, vol. 54, No. 5,1992, pp. 795-801. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jan. 25, 2006, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated May 30, 2007, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jul. 22, 2005, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Apr. 22, 2008, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Sep. 25, 2009, 8 pages. |
Non-Final Office Action; U.S. Appl. No. 11/435,502; dated Jul. 17, 2009, 10 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Apr. 12, 2010, 11 pages. |
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Aug. 3, 2011, 13 pages. |
Non-Final Office Action; U.S. Appl. No. 11/558,046; dated Jul. 12, 2010, 14 pages. |
Non-Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 12, 2010, 9 pages. |
Non-Final Office Action; U.S. Appl. No. 11/777,992; dated Jun. 22, 2012, 5 pages. |
Non-Final Office Action; U.S. Appl. No. 12/337,544; dated Mar. 30, 2012, 13 pgs. |
Non-Final Office Action; U.S. Appl. No. 12/565,613; dated Sep. 23, 2011, 32 pages. |
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Mar. 7, 2011, 6 pages. |
Non-Final Office Action; U.S. Appl. No. 13/616,633; dated Oct. 3, 2016; 18 pages. |
Non-Final Office Action; U.S. Appl. No. 11/359,092; dated Nov. 19, 2009, 13 pages. |
Notice of Opposition to European Patent No. EP2162083; Date of Opposition Aug. 31, 2016; 70 pages. |
Notice of Opposition to European Patent No. EP2162083; Date of Opposition Sep. 22, 2016; 70 pages. |
Nurnberger, F. “So-Called Cellulite: An Invented Disease,” Journal of Dermatologic Surgery and Oncology, Mar. 1978, pp. 221-229. |
Office Action dated Jun. 4, 2012 in Japanese Patent Application No. 2010-509318, 8 pages. |
Office Action dated Nov. 15, 2013 in Japanese Patent Application No. 2012-225924, 12 pages. |
Pease, G. R. et al., “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering, vol. 117, Feb. 1995, pp. 59-63. |
Pech, P. et al., “Attenuation Values, Volume Changes and Artifacts in Tissue Due to Freezing,” Acta Radiologica ,vol. 28, Issue 6, 1987, pp. 779-782. |
Peterson, L. J. et al., “Bilateral Fat Necrosis of the Scrotum,” Journal of Urology, vol. 116, 1976, pp. 825-826. |
Phinney, S. D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” The American Journal of Clinical Nutrition, vol. 60, 1994, pp. 725-729. |
Pierard, G.E. et al., “Cellulite: From Standing Fat Herniation to Hypodermal Stretch Marks,” The American Journal of Dermatology, vol. 22, Issue 1, 2000, pp. 34-37, [Abstract]. |
Pope, K. et al. “Selective Fibrous Septae Heating: An Additional Mechanism of Action for Capacitively Coupled Monopolar Radiofrequency” Thermage, Inc. Article, Feb. 2005, 6pgs. |
Pre-Interview Office Action; U.S. Appl. No. 11/434,478; dated May 6, 2010, 4 pages. |
Quinn, P. J. “A Lipid-Phase Separation Model of Low-Temperature Damage to Biological Membranes,” Cryobiology, 22, 1985, 128-146. |
Rabi, T. et al., “Metabolic Adaptations in Brown Adipose Tissue of the Hamster in Extreme Ambient Temperatures,” American Journal of Physiology, vol. 231, Issue 1, Jul. 1976, pp. 153-160. |
Renold, A.E. et al. “Adipose Tissue” in Handbook of Physiology, Chapter 15, (Washington, D.C., 1965) pp. 169-176. |
Rossi, A. B. R. et al. “Cellulite: a Review,” European Academy of Dermatology and Venereology, 2000, pp. 251-262, 12 pgs. |
Rubinsky, B. et al., “Cryosurgery: Advances in the Application of low Temperatures to Medicine,” International Journal of Refrigeration, vol. 14, Jul. 1991, pp. 190-199. |
Rubinsky, B., “Principles of Low Temperature Cell Preservation,” Heart Failure Reviews, 8, 277-284, 2003. |
Saleh, K.Y. et al., “Two-Dimensional Ultrasound Phased Array Design for Tissue Ablation for Treatment of Benign Prostatic Hyperplasia,” International Journal of Hyperthermia, vol. 20, No. 1, Feb. 2004, pp. 7-31. |
Schoning, P. et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology 27, 1990, pp. 189-193. |
Second Examination Report dated Jun. 27, 2012 in Australian Patent Application No. 2007353791, 3 pages. |
Shephard, R. J. “Adaptation to Exercise in the Cold,” Sports Medicine, vol. 2, 1985, pp. 59-71. |
Sigma-Aldrich “Poly(ethylene glycol) and Poly(ethylene oxide),” http://www.sigmaaldrich.com/materials-science/materialscience-;products.htmi?TablePage=2020411 0, accessed Oct. 19, 2012. |
Smalls, L. K. et al. “Quantitative Model of Cellulite: Three Dimensional Skin Surface Topography, Biophysical Characterization, and Relationship to Human Perception,” International Journal of Cosmetic Science, vol. 27, Issue 5, Oct. 2005, 17 pgs. |
Thermage, News Release, “Study Published in Facial Plastic Surgery Journal Finds Selective Heating of Fibrous Septae Key to Success and Safety of Thermage ThermaCool System,” Jun. 20, 2005, 2 pages. |
U.S. Appl. No. 11/528,189 for Levinson et al., filed Sep. 26, 2006. |
U.S. Appl. No. 12/275,002 for Martens, filed Nov. 20, 2008. |
U.S. Appl. No. 12/275,014 for Martens, filed Nov. 20, 2008. |
Vallerand et al., “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans,” Aviation, Space, and Environmental Medicine 70(1), 1999, pp. 42-50. |
Vuraki et al.; A device for cryo vacuum treatment; Med tech, Jan.-Feb. 1989, (1):46-9 (extracted from Pubmed on Dec. 6, 2016). |
Wang, X. et al., “Cryopreservation of Cell/Hydrogel Constructs Based on a new Cell-Assembling Technique,” Sep. 5, 2009, 40 pages. |
Wharton, D. A. et al., “Cold Acclimation and Cryoprotectants in a Freeze-Tolerant Antarctic Nematode, Panagrolaimus Davidi,”, Journal of Comparative Physiology, vol. 170, No. 4, Mar. 2000, 2 pages. |
Winkler, C. et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” in Transgenic Animals, Generation and Use (The Netherlands 1997), pp. 387-395. |
Young, H. E. et al. “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells” The Journal of Tissue Culture Methods, vol. 14, Issue 2, 1992, pp. 85-92. |
Zelickson, B. et al., “Cryolipolysis for Noninvasive Fat Cell Destruction: Initial Results from a Pig Model”, 35 Dermatol. Sug., 2009, pp. 1-9. |
Zouboulis, C. C. et al., “Current Developments and Uses of Cryosurgery in the Treatment of Keloids and Hypertrophic Scars,” Wound Repair and Regeneration, vol. 10, No. 2, 2002, pp. 98-102. |
Final Office Action; U.S. Appl. No. 13/616,633; dated Feb. 12, 2016, 22 pages. |
Final Office Action; U.S. Appl. No. 13/616,633; dated May 18, 2017, 20 pages. |
Final Office Action; U.S. Appl. No. 15/815,454; dated Aug. 6, 2018 19 pages. |
International Search Report and Written Opinion for PCT/US2012/022585; dated May 18, 2012, 14 pages. |
International Search Report for Applicant: PCT/US2007/075935; Zeltiq Aesthetics, Inc; dated Apr. 10, 2008, 4 pages. |
Non-Final Office Action; U.S. Appl. No. 11/750,953; dated Apr. 28, 11, 24 pages. |
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Jun. 30, 2011, 10 pages. |
Non-Final Office Action; U.S. Appl. No. 13/616,633; dated Sep. 11, 2015; 22 pages. |
Non-Final Office Action; U.S. Appl. No. 15/815,454; dated Feb. 28, 2018; 23 pages. |
Notice of Allowance; U.S. Appl. No. 15/815,454; dated Apr. 8, 2019, 9 pages. |
Office Action dated Aug. 29, 2011 in Japanese Patent Application No. 2010-509318, 9 pages, with English translation. |
Number | Date | Country | |
---|---|---|---|
20190365595 A1 | Dec 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15815454 | Nov 2017 | US |
Child | 16542182 | US | |
Parent | 13616633 | Sep 2012 | US |
Child | 15815454 | US | |
Parent | 11750953 | May 2007 | US |
Child | 13616633 | US |